Nucleotide Inhibition of Glyoxalase II by Gillis, Glen S
APPROVED:
Scott J. Norton, Major Professor
Ruth Anne Massarachia, Committee Member
Manus Donahue, Committee Member
Kent Chapman, Committee Member
Gerald A. O’Donovan, Committee Member and Chair of
the Department of Biological Sciences
C. Neal Tate, Dean of the Robert B. Toulouse School of
Graduate Studies
NUCLEOTIDE INHIBITION OF GLYOXALASE II
Glen S. Gillis
Prepared for the Degree of
DOCTOR OF PHILOSOPHY
UNIVERSITY OF NORTH TEXAS
May 1999
Gillis, Glen S., Nucleotide Inhibition of Glyoxalase II.  Doctor of Philosophy
(Biochemistry), May 1999, 210 pp., 8 tables, 38 illustrations, references, 243 titles.
The glyoxalase system mediates the conversion of methylglyoxal, a toxic
ketoaldehyde, to D-lactic acid.  The system is composed of two enzymes, glyoxalase I
(Glo-I) and glyoxalase II (Glo-II), and exhibits an absolute requirement for a catalytic
quantity of glutathione (GSH).  Glo-I catalyzes the isomerization of a hemithioacetal,
formed non-enzymatically from methylglyoxal and GSH, to the corresponding α-D-
hydroxyacid thioester, s-D-lactoylglutathione (SLG). Glo-II catalyzes the irreversible
breakdown of SLG to D-lactate and GSH.
We have observed that ATP or GTP significantly inhibits the Glo-II activity of
tissue homogenates from various sources.  We have developed a rapid, one step
chromatography procedure to purify Glo-II such that the purified enzyme remains
“sensitive” to inhibition by ATP or GTP (Glo-II-s).  Studies indicate that inhibition of
Glo-II-s by nucleotides is restricted to ATP, GTP, ADP, and GDP, with ATP appearing
most effective.  Kinetics studies have shown that ATP acts as a partial non-competitive
inhibitor of Glo-II-s activity, and further suggest that two kinetically distinguishable
forms of the enzyme exist.
The sensitivity of pure Glo-II-s to nucleotide inhibition is slowly lost on storage
even at -80°C.  This loss is accelerated at higher temperatures or in the presence of ATP.
Kinetics studies on the resultant “insensitive” enzyme (Glo-II-i) show that a significant
reduction of the affinity of the enzyme for the substrate, SLG, occurs and further suggest
that only one form of the enzyme is kinetically distinguishable after “de-sensitization”.
Tryptophan fluorescence studies of the two enzyme preparations suggest that a subtle
conformational change in the enzyme has occurred during de-sensitization.
We have also observed that Glo-II-i is “resensitized” to nucleotide inhibition after
incubation in the presence of a reagent that reduces disulfide bonds.  The resensitized
enzyme exhibits an increased KM value similar to that of the original Glo-II-s.  Kinetics
studies show that ATP or GTP again act as partial non-competitive inhibitors of the
resensitized enzyme and suggest that only one form of the enzyme is present.  The
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In living systems, the glyoxalase system mediates the detoxification of toxic α-
ketoaldehydes by catalyzing their conversion to the corresponding non-toxic carboxylic
acids (see Fig. 1).  The primary role of glyoxalase activity is considered to be the
conversion of methylglyoxal, a toxic α-ketoaldehyde derived from both endogenous and
exogenous sources, to lactic acid (1).  The system is composed of two enzymes,
glyoxalase I (E.C. 4.4.1.5, lactoylglutathione lyase) (Glo-I) and glyoxalase II
(E.C. 3.1.2.6, hydroxyacylglutathione hydrolyase) (Glo-II), and exhibits an absolute
requirement for a catalytic quantity of reduced glutathione (GSH) (2).
R-COCHO (α-ketoaldehyde)
 R-COCH (OH)-SG (hemithioacetal)
         GSH Glo-I
R-CH (OH) CO-SG (α-D-hydroxyacidthiol ester)
Glo-II
R-CH (OH) CO2H (α-D-hydroxyacid)
2
The first step of the glyoxalase system involves the non-enzymatic formation of
the physiological substrate of Glo-I, a hemithioacetal from the α-ketoaldehyde and
reduced GSH (2).
In the second reaction, Glo-I catalyzes the isomerization of either of the
stereoisomers of the hemithioacetal to the corresponding α-D-hydroxyacid thioester (2).
 The third and final reaction is an enzymatic hydrolysis in which Glo-II catalyzes
the breakdown of the α-D-hydroxyacid thioester to the corresponding α-D-hydroxyacid.
Reduced GSH is recycled in the reaction (2).
1.2 History
In 1913, two independent research groups discovered that organisms could readily
convert certain α-ketoaldehydes to their corresponding α-hydroxycarboxylic acids (3,4).
In particular, the addition of phenylglyoxal or methylglyoxal to the cytosolic extracts
from yeast, plant, or animal sources resulted in the production of mandelic or lactic acid,
respectively (3-5).  Activity was measured as the production of lactic acid either by
detecting changes in the optical rotation of the reaction solution (6-7), or by manometric
determination of the release of carbon dioxide from a bicarbonate buffered reaction
solution following acidification (1,8).  This activity, originally thought to be due to the
presence of a single enzyme, was named glyoxalase (3, 4).
In 1932, research interests in the field of glyoxalase were motivated by the
discovery that GSH was an essential co-factor for the reaction (1).  This renewed interest
in glyoxalase activity led to the detection of a complex formed from the non-enzymatic
reaction of α-ketoaldehydes with reduced GSH (9).  This complex, a hemithioacetal, had
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been proposed as being the true substrate for glyoxalase activity.  An alternative path, in
which glyoxalase activity utilizes both GSH and methylglyoxal as substrates in a bi-
molecular substrate reaction, has also been proposed (10,11).
In 1936, further research into the mechanism of glyoxalase activity led to the
detection of a novel intermediate that was formed by glyoxalase activity subsequent to
the addition of methylglyoxal to liver extracts (12).  This compound, distinct from that of
the hemithioacetal adduct, was proposed as being formed initially from the
hemithioacetal and then subsequently converted to the carboxylic acid product by
glyoxalase activity.  The isolation and identification of this intermediate proved to be an
obstacle that impaired further developments in this field for the next fifteen years.
It was not until 1951, when Racker (2) discovered that glyoxalase activity was
dependent on the presence of two distinct enzymes, that the pathway from
α-ketoaldehydes to their corresponding α-hydroxycarboxylic acids was resolved.
Furthermore, he isolated and identified the aforementioned novel intermediate S-D-
lactoylglutathione (SLG), the methylglyoxal-derived α-hydroxyacidthioester.  This
discovery led to the development of a direct spectrophotometric assay for the rate of the
formation or of the degradation of SLG that could be utilized to measure the glyoxalase
activity of cell extracts.
Racker proposed that the first enzymatic reaction of this pathway involved the
conversion of the α-ketoaldehyde/GSH substrate (hemithioacetal) to the corresponding
α-D-hydroxyacid-thioester.  Support for this proposal was obtained by demonstrating that
this reaction, when utilizing methylglyoxal as the α-ketoaldehyde, subsequently produced
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the corresponding α-D-hydroxyacid-thioester, SLG.  Racker also proposed that the
product of the first enzymatic reaction was the substrate for a second enzymatic reaction.
Support for this proposal was obtained from demonstrating that the α-D-hydroxyacid-
thioester derived from methylglyoxal, SLG, was converted to the corresponding α-
hydroxyacid, lactic acid by a second enzymatic reaction. The enzymes involved were
named glyoxalase I (Glo-I) and glyoxalase II (Glo-II), the name of each enzyme
corresponding to the reaction order in which they appear.
The discoveries of Racker were dominant in stimulating further research interest
in the glyoxalase system.  Furthermore, his contributions provided many of the basic
tools from which further research in this field could be conducted; in fact, the assay
methods he developed are still in use today.
1.3  Proposed Functional Roles of the Glyoxalase System
Several possible physiological functions of the glyoxalase system have been
proposed over the years.  These include a glycolytic bypass, control of the cell cycle,
involvement in tubulin dynamics, as well as the detoxification of α-ketoaldehydes.
  Originally, the glyoxalase system was proposed as being associated with
glycolysis by providing an alternate pathway for the metabolism of triose phosphates to
pyruvate via methylglyoxal and lactic acid.  This proposal may still carry some merit
with respect to prokaryotes, as E. coli cells have been shown to convert dihydroxyacetone
phosphate to pyruvate via the glyoxalase pathway in an efficient manner (13, 14).  In
higher organisms, the exclusive production of the L isomer of lactic acid in glycolysis
(15), coupled with Racker’s discovery that glyoxalase activity produced only the D
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isomer of lactate (16) suggested no direct interaction between the two systems.
Furthermore, the demonstration that glyoxalase activity is not required for glycolysis to
occur shed even more doubt on this proposal (1).
In the 1960’s, a research group headed by Szent-Gyorgyi proposed a possible role
for the involvement of the glyoxalase system in the regulation of the cell cycle (17, 18).
They proposed that the concentration of a universal inhibitory growth factor, a
ketoaldehyde derivative they named “retine”, regulated the growth of a cell.  This factor
was reported to be undetectable in rapidly proliferating cancer cells.  As ketoaldehydes
were the known substrates for the glyoxalase system, it was proposed that glyoxalase
might regulate the physiological concentration of such regulatory ketoaldehydes.
Decades of research subsequent to this proposal have provided mounting evidence to the
contrary but little support for the validity of this theory.  Nevertheless, this proposal did
stimulate further research and consequently a deeper understanding of the glyoxalase
system.
There has been mounting evidence to implicate the involvement of the glyoxalase
system in the dynamics of tubulin polymerization, although this evidence remains
somewhat ambiguous.  In cell free conditions, methylglyoxal has been shown to inhibit
the formation of microtubules (19), although only at concentrations far above the
reported physiological levels of the metabolite (20).  The effect of SLG on the in vitro
assembly of microtubules is indeterminate, with both the potentiation and the inhibition
of microtubule assembly being observed (21).  The exogenous addition of SLG to cell
cultures has been observed to cause an inhibitory effect upon microtubule-dependent
events such as the functional activation of neutrophils (22) and the secretion of histamine
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from basophiles (23). Even so, these results should be viewed with caution, as SLG has
little membrane permeability and it is believed to be produced and metabolized only in
the cytosol of the cell (24). As a number of studies implicated the involvement of the
SLG in microtubule dynamics, further research was prompted. Norton et al (25)
synthesized a number of highly specific Glo-II inhibitors that acted as very slow
substrates for the enzyme. Of those inhibitors synthesized, the N,S-
bisflourenylmethoxycarbonyl GSH (DiFMOC-G), exhibited the greatest affinity for the
enzyme. To increase the membrane permeability of this inhibitor, esters of DiFMOC-G
were synthesized.  It was anticipated that such inhibitors would specifically increase
intracellular concentrations of SLG for a period until their degradation.  Indeed, these
inhibitors exhibited profound inhibitory effects on early tubulin dynamics (two day
cultures) but demonstrated no visible effect after longer incubation periods (15 day
cultures).
The possibility of an association of Glo-II and microtubules was also investigated
by Norton et al (25).  Significant thioesterase activity was detected in tubulin
preparations even after three association / dissociation cycles of purification.  In addition,
the thioesterase activity that co-pelleted with the tubulin preparations appeared to
undergo changes in substrate specificity.  Furthermore, immunochemical techniques have
demonstrated a direct physical association of Glo-II with tubulin (25).  Presently, the role
of the glyoxalase system with respect to tubulin dynamics, if any, remains uncertain.
The major role of the glyoxalase system is considered to be that of methylglyoxal
detoxification (26, 27).  Methylglyoxal is considered a toxic substance that is cytostatic at
low concentrations and cytotoxic at higher concentration (28).  This compound is
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produced endogenously in a number of different ways, primarily as an unavoidable by-
product of triose phosphate metabolism (29-32).  It can also be found in the diet of many
higher animals (33, 34).  Furthermore, a number of strains of bacteria, including
enterobacteria, form methylglyoxal enzymatically through the action of methylglyoxal
synthase (35).  Although other systems exist that are capable of removing methylglyoxal
from living systems, the majority of this toxic metabolite is thought to be processed
through the glyoxalase system.
1.4  Distribution of the Glyoxalase System
Glyoxalase activity was proposed to be ubiquitous as early as 1945: it has been
found at varying levels in all forms of life studied to date including mammals, plants,
yeast, and a number of strains of bacteria (3, 4, 5, 35).
The enzymes of the glyoxalase system do not appear to be restricted to any
particular tissue in higher organisms, although the specific activity of each enzyme does
vary from tissue to tissue.  In humans, the highest activity of Glo-I is found in the lung,
kidney, pancreas, and brain and is least evident in the liver and adipose tissues. (36).
Fetal tissue is reported to exhibit a three-fold increase in Glo-I activity over
corresponding non-fetal tissues (36).  The activity of Glo-II in humans is greatest in the
brain, liver, and muscle, with significantly less activity being present in the spleen and
pancreas (37).  A number of cancerous tissues are reported to exhibit a major decrease in
Glo-II activity when compared to the corresponding non-cancerous tissue (38).
The greater portion of glyoxalase activity is generally found in the cytosolic
fraction of cells, although some glyoxalase activity has been reported to exist in cellular
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organelles.  In particular, Glo-I activity has been detected in permeabilized endoplasmic
reticulum (36) while up to 15% of the total Glo-II activity of a cell may be found in
mitochondria (39).
1.5  Methylglyoxal
1.5.1  Sources of Methylglyoxal
The physiological substrate for the glyoxalase system is methylglyoxal.  In higher
organisms, the primary endogenous source of methylglyoxal occurs from the spontaneous
elimination of phosphate from triose phosphates, primarily dihydroxyacetone phosphate
and to a lesser extent glyceraldehyde-3-phosphate (29).  Enzymatic sources of
endogenous methylglyoxal include leakage of the bound phospho-ene-diolate from the
active site of triose phosphate isomerase (30) and, to a lesser extent, leakage from the
active site of the aldolase reaction with glyceraldehyde-3-phosphate (40).  Another,
although minor endogenous source of methylglyoxal is the action of amine oxidase on
aminoacetone, an intermediate in threonine catabolism (41, 42).  Still another endogenous
source occurs from the conversion of hydroxyacetone, an intermediate in the metabolism
of acetone and isopropanol, to methylglyoxal by the action of acetol dehydrogenase (43-
45).
Exogenous sources of methylglyoxal in many higher organisms, including
humans, are diet and bacteria.  Methylglyoxal is an unavoidable consequence of a daily
human diet since common beverages and foods such as brewed coffee, cola, juices, toast
and tobacco are known to contain significant quantities of methylglyoxal (33, 34).
Bacteria provide another source as a number of strains have been shown to produce
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methylglyoxal (35), primarily through the action of an enzyme unique to prokaryotes,
methylglyoxal synthase.  As previously mentioned, enterobacteria have been found to
produce methylglyoxal in the same manner (26).  This enzyme is inhibited by inorganic
phosphate (Pi).  Thus it is activated only when the levels of inorganic phosphate are low,
and its action frees inorganic phosphate from dihydroxyacetonephosphate to form
methylglyoxal (46).
1.5.2  Metabolism of Methylglyoxal
Methylglyoxal can be metabolized by a number of systems other than the
glyoxalase system.  Other enzymes known to metabolize methylglyoxal include aldose
reductase, methylglyoxal dehydrogenase, and methylglyoxal reductase.
Aldose reductase (E.C.  1.1.1.21) catalyzes the formation of hydroxyacetone from
methylglyoxal using NADPH as a co-factor (47).  Although glyceraldehyde is believed to
be the natural substrate for the enzyme, this study indicated that methylglyoxal can also
serves as an efficient substrate (47).  The enzyme has been shown to exhibit comparable
KM values for these substrates (8 µM for methylglyoxal, 16 µM for D-glyceraldehyde
and 42 µM for L-glyceraldehyde), while the kcat / KM for methylglyoxal (107) is one order
of magnitude greater than that of glyceraldehyde.
Methylglyoxal dehydrogenase (E.C.  1.2.1.23) catalyzes the oxidation of
methylglyoxal directly to pyruvate.  It has been isolated from microorganisms, which use
NAD+ as a cofactor (48), and from human liver, which requires either NAD+ or NADP+
as a cofactor (49).  The KM values exhibited by the enzyme for methylglyoxal are quite
high; 4.5 mM and 0.4 mM for the enzymes that require NAD+ and NADP+, respectively.
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Methylglyoxal reductase catalyzes the formation of L-lactaldehyde from
methylglyoxal using either NADH (mammalian) (50) or NADPH (yeast) (51) as a
co-factor.  This enzyme has been purified from goat liver but its involvement in the
physiological metabolism of methylglyoxal is unknown.
1.5.3  Methylglyoxal – Concentration and Reactivity
The concentration of methylglyoxal in tissue extracts is assayed by determining
the amount of chromophoric adduct formed between the ketoaldehyde and o-phenylene
diamine.  This procedure requires the separation of the adduct from other interfering
chromophores by high-pressure liquid chromatography (52, 53).  The concentration of
methylglyoxal in tissue samples generally remains in the low micromolar range (<3 µM)
but is significantly increased in many tissues from diabetic subjects (20, 54).
Methylglyoxal is considered a highly reactive, toxic metabolite although the
method by which this metabolite exhibits its toxic effect is still uncertain.  The
ketoaldehyde has been shown to react with both nucleosides and nucleotides,
preferentially those with guanine residues (55, 60).  Furthermore, methylglyoxal has been
reported to react with the amino acid residues of proteins, in particular arginyl residues
(61-68).  Finally, there is evidence that methylglyoxal inhibits the synthesis of cellular
proteins (28, 58, 69-71).
As stated previously, methylglyoxal has been shown to bind to both nucleosides
and nucleotides, preferentially those that possess the guanine moiety (55, 56).  In
experiments conducted with this ketoaldehyde to determine the extent of adduct
formation with DNA or RNA, no significant binding to DNA was detected until the DNA
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was denatured into single strands by heat denaturation.  The effect of methylglyoxal on
translation was at best weak when using either natural or chemically uncapped mRNA
(57, 58).  Methylglyoxal has been demonstrated to induce protein – DNA crosslinking in
Chinese hamster ovary cells; repair of these moieties occurs within 24 hr. after the
removal of the ketoaldehyde from the cell culture medium (59).  It was also reported to
induce sister chromatid exchange in the same cell line (60).  Although the effect of
methylglyoxal on nucleotide polymers was significant under these conditions, the
concentration of the toxic ketoaldehyde to produce such an effect was far above that of
physiological concentrations.  Therefore, the proposed role of methylglyoxal as a
mutagen or carcinogen in living organisms is probably not realized under conditions
where a normally functioning glyoxalase system is present.
Methylglyoxal toxicity appears to be related to its reactivity with proteins (61, 62,
63).  It has been shown that at physiological levels, methylglyoxal (1 µM) rapidly forms
reversible adducts with arginyl residues of proteins (61).  The position of equilibrium
suggests that up to 90% of the free α-ketoaldehyde exist in this form (64).  The
physiological relevance of these adducts has been demonstrated by their prevalence in
some disease states.  Methylglyoxal concentrations are known to increase significantly in
certain disease states such as diabetics, particularly in the lens (20, 54).  It has also been
demonstrated to bind in a rapid and efficient manner with gamma II-crystallins of both
human and animal lens, implicating these adducts in the process of cataract formation, a
common diabetic complication (65).  Recently, the methylglyoxal-arginyl adducts found
in proteins have been demonstrated to act as advanced glycation endproducts (66).  The
arginine-methylglyoxal adducts proved a potent signal for both the synthesis and
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secretion of macrophage-colony stimulation factor(67) as well as the degradation of
proteins by monocytic cells (68).
Methylglyoxal toxicity appears to be related to its effect on cell growth as well.
The addition of exogenous methylglyoxal to cell cultures is known to inhibit growth, a
consequence that can be reversed by the removal of the ketoaldehyde (69).  This effect
was found to be directly associated with the inhibition of protein synthesis (28), primarily
during the S and G2 phases of the cell cycle (70).  Further testing suggests that the effect
was not due to any direct interaction with DNA (70) or mRNA (58).  Anecdotal evidence
have led to the proposal that the inhibition of protein synthesis may be due to the
inactivation of either tRNA or ribosomal proteins due to formation of arginyl /
methylglyoxal adducts (71).
Much evidence suggests that methylglyoxal can cause damaging effects upon
living organisms; however, the efficiency of the glyoxalase system is thought to maintain
toxic α-ketoaldehydes at levels below physiological relevance.  It is therefore probable
that only when an inhibited or impaired glyoxalase system allows chronic levels of
methylglyoxal to be sustained that damage may follow.
1.6  S-D-lactoylglutathione
The product of GLO-1 activity with the methylglyoxal derived hemithioacetal
produces a high-energy intermediate, SLG.  Due to its poor membrane permeability, this
intermediate is thought to be produced and metabolized only in the cytosol of the cell
(24).  Physiological levels of SLG are generally found to be in the micromolar range with
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the concentrations of the intermediate being high in liver (>50 µM) and lower in the
kidney, lens, and blood (20, 54).
Interest in the role of SLG in biological systems was initially stimulated by the
discovery that this intermediate potentiates the polymerization of microtubules in vitro
(21). As stated earlier (see Section 1.2), although there is evidence that some type of
interaction between the glyoxalase system and tubulin does in fact occur, the nature of
such an interaction remains unknown.
Further interest in SLG has been motivated by studies that determined the change
in SLG concentration during the functional activation of blood cells.  Resting neutrophils,
upon activation by opsinized-zymosan (phagocytic activation) (72) or 12-O-
tetradecanoylphorbol 13 acetate (TPA) (73), undergo 100% increases in SLG levels,
independent of aerobic or anaerobic conditions.  Furthermore, the addition of exogenous
SLG has been shown to potentiate the rate of stimulus-induced secretion of histamine
from human leukocytes (23).
1.7  D-lactate
Only about 5% of the total lactate concentration of mammals is in the form of
D-lactate (74).  A significant source of D-lactate in higher organisms is that produced by
the enterobacteria of the gut (75).  Another source is that of a normal human diet (76, 77).
Although these sources contribute to the total D-lactate content of an organism, the major
source is considered to be that produced by the glyoxalase system (78).
  In humans, D-lactate is efficiently metabolized to pyruvate in mitochondria by an
FAD linked enzyme, 2-hydroxyacid dehydrogenase (E.C.  1.1.99.6) (79).  Transport
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through cell membranes is accomplished primarily via a specific lactate transporter,
although an inorganic anion exchange transport system and a non-ionic diffusion
mechanism are known to contribute (80).  D-lactate is also known to be efficiently
excreted in the urine, sweat, and stool (81 - 83).
 The concentration of D-lactate in mammals is highest in the liver and kidney, and
lowest in the lens and blood (20, 54, 82).  The concentration of this metabolite undergoes
2-3 fold increases in the blood after exercise or meals (77, 81 ).  In diabetic patients, 2-3
fold increases in D-lactate concentrations occur in blood plasma, while in streptozocin-
induced diabetic rats, the concentration of D-lactate was found to undergo significant
increases in the blood and lens (20, 54, 82).
1.8       Glyoxalase I
1.8.1    Glyoxalase I - Assay of Activity
Glo-I activity has been measured by a number of different methods.  One method
employs a coupled assay in which Glo-II has been added in excess; consequently the
formation of lactic acid becomes dependent on the conversion of methylglyoxal to SLG.
The formation of lactic acid can be followed by the manometric determination of the
release of CO2 from bicarbonate buffer after acidification (6,7).  A second method
involves following the rate at which methylglyoxal is consumed in the reaction by
titration of the remaining α-ketoaldehyde with semicarbazide (84).
The most widely used assay procedure to monitor Glo-I activity is the direct
spectrophotometric measurement of the formation of SLG at 240 nm
15
(ε = 3300 M-1 cm-1) using methylglyoxal as the substrate (85, 86, 87).  This procedure
requires the generation of the hemithioacetal by pre-incubation of the ketoaldehyde with
GSH (2 mM each), at pH 6.6, resulting in a hemithioacetal concentration of 0.63 mM
(Keq=333 M-1) before the addition of enzyme to the reaction mixture (87).  The major
drawback to this procedure stems from the interference of other compounds in the
reaction mixture that add to the total absorbance (ε = 440 M-1 cm-1 for the hemithioacetal,
ε = 115 M-1 cm-1 for GSH) (87).
1.8.2  Glyoxalase I - Distribution
Glo-I activity has been detected in all tissues of all organisms tested to date and
is therefore considered ubiquitous.  Activity has been detected in bacteria (88, 89),
parasitic protozoa (90, 91), fungi (92), tumors (37), and yeast (93, 94).  The enzyme has
been extensively purified initially from yeast (2), but has also been purified from the
erythrocytes of both rat (95) and pig (26), and from the liver of sheep (96), rabbit (97),
and mouse (98).  Glo-I activity has also been detected and studied in a number of plants
as well (99-101).
Table I summarizes the distribution of Glo-I in humans by both the measurement
of specific activity and by radioimmunoassay.  In humans, the tissue distribution of Glo-I
when determined by radioimmunoassay is highest in the spleen, liver, and adrenal gland
and lowest in adipose tissue (36).  It is interesting to note that the distribution of the
enzyme with respect to specific activity does not correlate with the radioimmunoassay
results.   Glo-I, when assayed with respect to the specific activity of the enzyme, exhibits
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the lowest activities in adipose and liver tissue, while the highest activities are found in
the lung, pancreas, kidney, and brain (36).  The enzyme exhibits three-fold increases in
specific activity in fetal tissue when compared to corresponding adult tissue (36).
Glo-I is thought to be a widespread, ubiquitous enzyme whose activity may be
dependent on the proliferative or active state of the tissue.  It has been suggested that the
activity of the enzyme in plants is regulated by a calmodulin-dependent calcium cascade
(99).   Inhibition of rapidly proliferating callus growth by calmodulin inhibitors was
correlated with a significant decrease in Glo-I activity, an effect that was overcome by
addition of endogenous calmodulin or by addition of inositol.  Soybean cell cultures that
were auxin dependent for proliferation were also observed to undergo increases in Glo-I
activity after the addition of auxin to the suspension (101). In mammals, certain disease
states have been demonstrated to cause increases in Glo-I activity.
In diabetic patients, activated mononuclear and polymorphonuclear cells from
patients, who exhibit diabetic complications, have significant elevation in Glo-I activity
(102).  Rapidly proliferating cells from colon tumors also show increases in Glo-I activity
(103).  The activity of Glo-I was also demonstrated to increase in regenerating mouse
liver as well (104).  Conversely, tissue samples from aged rats, tissues believed to exhibit
reduced proliferative capabilities, had a significant decrease in Glo-I activity (105).
Further research is warranted to determine the mode by which these changes in activity
occur.
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1.8.3  Glyoxalase I - Molecular Characteristics
The molecular properties of Glo-I from higher mammals are quite different from
those of lower organisms such as yeast and bacteria (see Table II). In all species, Glo-I is
a metallo-enzyme that contains one zinc ion per subunit that is required for catalytic
activity and / or structural integrity.
The mammalian enzyme exists as a dimer of two similar subunits.  In humans,
these subunits are expressed at a diallelic gene locus GLO that encodes three possible
allozymes, GLO-1 1-1, GLO-1 1-2, and GLO-1 2-2 (106).  These allozymes are known to be
kinetically indistinguishable (107, 108) but can be separated by ion-exchange
chromatography (107) or native gel electrophoresis (109).  The estimated molecular
weight of the dimer is 46 kDa, as determined by the Stokes radius and sedimentation
coefficient (93).  The molecular weight of the single subunit has been estimated at 23
kDa by SDS-PAGE (110).  In contrast, the enzyme from yeast or bacterial sources exists
only in the monomer state with a molecular weight ranging from 31 - 35 kDa (93, 111,
112).
Other differences between the mammalian enzyme and the yeast and / or bacterial
enzyme exist as well.  One such difference is that of the isoelectric point of the enzymes.
The isoelectric point of the yeast enzyme is at neutral pH (113), while the mammalian
and bacterial enzymes are acidic enzymes with isoelectric points of 4.8 and 4.0
respectively (114).  Another difference in these enzymes is their different affinities for
the accepted physiological substrate, methylglyoxal.  The KM values of the mammalian
and yeast enzymes, using methylglyoxal as a substrate, are 0.12 mM and 0.53 mM
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respectively (107), and are significantly lower than the KM value of 3.5 mM for the
bacterial enzyme using the same substrate (89).
Still another difference in these enzymes lies in the ability of the apoenzymes to
be reactivated after removal of the prosthetic zinc ion.  The enzyme from all sources
contains one Zn2+ ion per subunit (115), but, after removal of the ion by chelation, only
the mammalian apoenzyme can be reactivated by the addition of zinc.  Furthermore, the
mammalian enzyme is responsive to metal ion exchange.  The apoenzyme from
mammalian sources can be reactivated to nearly 100% of the original activity by the
addition of magnesium (11, 96, 115-120).  Other ions, such as Mn2+, Co2+, Ni2+, Ca2+,
V2+, and Ga2+, can also reactivate the enzyme to a lesser extent.   Cd2+, Ba2+, Fe2+, and
Hg2+ were found to be ineffective (11, 96, 115-120).
Although the enzyme from mammals is considered immunologically distinct from
that of yeast and bacteria (36), recent reports show that the amino acid sequence of Glo-I
exhibits a large degree of homology throughout nature (121).  The primary structure of
the yeast enzyme appears to consist of two similar segments with each segment being
homologous to the mammalian monomer.  This is believed to have occurred due to gene
duplication, resulting in a fused dimer.  The bacterial enzyme exhibits up to 50%
sequence homology with the human enzyme as well (122).  Therefore, although the
enzymes do exhibit a number of differences, it is likely that all have been derived from a
common ancestor.
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1.8.4  Glyoxalase I – Substrate Specificity, Kinetics, and Catalytic Mechanism
 With respect to substrate specificity, Glo-I accepts a broad range of α-
ketoaldehydes as substrates (2, 87, 95, 123-129).  The enzyme readily accepts both
aromatic and aliphatic compounds of this class regardless of the source of the enzyme,
microbial or mammalian.  The broad specificity of the enzyme for α-ketoaldehyde
substrates is indicative of the role of the glyoxalase system in detoxification.  Other
detoxification systems such as the cytochrome P-450 system (130) and GSH-S-
transferase isozymes (131) exhibit such broad specificities as well.
In contrast to the ability of Glo-I to accept a variety of α-ketoaldehyde substrates,
the coenzyme specificity of Glo-I is essentially restricted to the GSH moiety (1).  Certain
GSH analogs such as homoglutathione (132), isoglutathione, asparthione (133), and
others (134, 135) can replace GSH as an active cofactor, although the efficiency of these
compounds as cofactors is greatly reduced in comparison to GSH itself.  Generally, any
hemithioacetal derived from an analog of GSH, which serves as a cofactor for Glo-I
activity, exhibits a greatly reduced affinity for the enzyme as reflected in the KM values
for such substrates.  It should be noted that although any change in the GSH structure
does lower the affinity of Glo-I for the respective substrate, no significant change in the
maximum velocity of the enzyme is observed.  Therefore the role of GSH with respect to
Glo-I activity is thought to be related to enzyme recognition.
The hemithioacetal complex formed from methylglyoxal and GSH is generally
assumed as being the substrate for Glo-I, although a two-substrate reaction has never
been conclusively ruled out.  The assumption for a one-substrate reaction has been based
upon “burst” kinetic studies carried out at high substrate concentrations, in which the
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addition of increasing levels of Glo-I to assay mixtures did not increase the rate of SLG
formation over and above the rate of hemithioacetal formation (126, 136).  Although
these results support a one-substrate reaction mechanism, studies carried out at low
substrate concentrations (<< KM) resulted in non-linear curvature of the Dixon plots
indicating that a combination of both one-substrate and two-substrate reactions may be
possible (137, 138).
Glo-I follows Michaelis – Menten kinetics over a substrate range up to 0.67 mM
in the presence of a constant amount of reduced GSH (139).  The values of the Michaelis
constant, KM, are 0.13 mM and 0.53 mM for the mammalian and yeast enzymes
respectively utilizing the methylglyoxal-derived hemithioacetal as a substrate (107).  The
turnover numbers, kcat, range from 59,000-70,000 min
-1 for the mammalian enzyme and
109,000 min-1 for the enzyme from yeast.  The catalytic efficiency of the enzymes, kcat /
KM, approaches values of 10
7, a value near the theoretical limits of diffusion.  GSH itself
acts as a competitive inhibitor of Glo-I activity, although the KI values, estimated to be as
high as 7.9 mM (140) to 18 mM (110), are likely too high to be physiologically relevant.
The reaction has been demonstrated to be reversible, although the predicted equilibrium
for the reaction lies far to the right in favor of isomerization of the hemithioacetal to SLG
(139).
   Chemical modification studies have identified a number of possible active site
residues.  In modification studies, incubation of the enzyme with sulfhydryl group
reagents causes the complete inactivation of the enzyme from yeast (141) but have no
effect on the activity of the enzyme from mammalian sources (142, 143).  Studies
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indicate that the enzyme has two free sulfhydryl groups per monomer, four in total for the
mammalian dimer and two for the yeast enzyme (93).
Modification of two arginine residues by specific reagents also causes complete
loss of catalytic activity (144).  The addition of substrate provides effective protection
against the loss of activity by preventing the modification of one of the affected arginine
residues (144).  Results have been interpreted as indicating the presence of an active site
arginine essential for catalytic activity.
Modification of Glo-I by tryptophan specific reagents also causes complete
inactivation of the enzyme activity (145, 146).  One study indicated that a total of three
tryptophan residues are modified, the addition of substrate protects the enzyme from
modification, and the loss of activity result from the modification of only one of the
tryptophan residues (145).  Results were interpreted as indicating the presence of an
active site tryptophan essential for catalytic activity.
The nitration of tyrosine residues also causes complete inactivation of the enzyme
(146).  The addition of substrate provides effective protection against the loss of activity
(146).  It is not yet clear whether the residue modified is involved with the binding of
substrate or the coordination of the zinc ion (117).
Other studies have shown that the metal ion is located near the active site (116,
120).  Although the presence of a metal ion is required for catalysis, the ability of the
mammalian enzyme to accept a number of metal ions while remaining enzymatically
active indicates that the role of the metal ion may be to provide structural integrity to the
protein.
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 The reaction catalyzed by Glo-I involves the conversion of the hemithioacetal
substrate to the corresponding α-D-hydroxyacid-thioester product via an isomerization
reaction.  Isotopic experiments have indicated that an exchange of protons from water is
unlikely (147, 148); therefore, the isomerization likely involves a shielded proton transfer
from the C1 to the C2 of the bound substrate (149), a mechanism which would result in
an ene-diol intermediate.  Experiments involving isotopic substrates are in agreement
with this mechanism (111).  Further studies utilizing flavinoid derivatives, compounds
known to trap ene-diol intermediates, also support this mechanism (150, 151).
The enzyme has been demonstrated as being able to accept both epimeric forms
of hemithioacetal substrates, an advantage that is thought to increase the efficiency of the
Glo-I in its role as a detoxification enzyme (149).  Although the enzyme is not
stereoselective with respect to substrate, Glo-I is known to form only the D isomer of
SLG from the methylglyoxal-derived substrate in a stereospecific manner.
1.8.5  Glyoxalase I - Inhibitors
Inhibitors of Glo-I have been investigated for a number of reasons, one being to
study the mechanism by which the reaction occurs.  Mechanism based inhibitors, such as
those that mimic the proposed ene-diol intermediate, have been studied extensively.
Such compounds have been demonstrated to be potent Glo-I inhibitors (152, 153).
Substituted coumarin derivatives such as isoesculetin and 4-methylcoumarin are
examples of ene-diol mimics that potently inhibit Glo-I activity.  Flavone derivatives that
are also known to trap ene-diol intermediates, such as quercetin, myricetin, and taxifolin,
also are inhibitory.
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A number of substrate analog inhibitors of Glo-I have been developed as specific
agents against the growth of cancerous tissue (154).  Glo-II activity has been reported as
being greatly decreased in many cancerous tissues when compared to corresponding non-
cancerous tissue (37).  Theoretically, specific Glo-I inhibitors, which act as slow
substrates for Glo-II activity, would be removed efficiently from normal cells by Glo-II.
In contrast, cancerous tissues, which possess significantly reduced Glo-II activity, would
be unable to hydrolyze the Glo-I inhibitor efficiently, resulting in the specific increase of
cytotoxic methylglyoxal in cancerous tissues.
Substrate analog inhibitors of Glo-II include S- and N- terminal substituted
derivatives of GSH  (154).  S- Alkylglutathione derivatives exhibit an increase in
inhibitory capability corresponding to an increase in the chain length of the alkyl moiety
(154), suggesting the existence of a hydrophobic pocket in the active site of the enzyme
which facilitates binding (154, 155).  Studies indicate that the N-terminal substituent does
not contribute to the specificity of the substrate binding in the mammalian enzyme (155).
1.8.6  Glyoxalase I – Genetics and Cloning
As stated earlier, human Glo-I is expressed at a diallelic gene locus, GLO, which
encodes three possible allozymes, GLO-1 1-1, GLO-1 1-2, and GLO-1 2-2 (106, 157).
Again, these allozymes are known to be kinetically indistinguishable but can be separated
by ion-exchange chromatography (107) or native gel electrophoresis (109).  Inheritance
of these alleles follows an autosomal diallelic codominant pattern.  The two alleles appear
in the genomes of both rat (158) and mouse (159) as well.  The GLO-1 2 allele is thought
to have been the original gene in the genome, while the GLO-1 1 allele is thought to have
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occurred due to gene duplication followed by mutation (160).  The gene for Glo-I is
found on chromosome 6 and is tightly linked to the Human Leukocyte System A (HLA)
gene complex (161) in humans, the H-2 gene complex in mice (159), and the Major
Histocompatability Complex in rats (158).  The expression of the alleles in humans seems
to follow specific geographic regularity in that the frequency of the GLO-1
1
 allele is
extremely low in Asian populations, exists at medium frequencies in African populations,
and appears at the highest frequencies in Caucasian populations (162).
The cDNA of Glo-I from a human colon library has been isolated and sequenced
and has been demonstrated to express a 180 amino acid protein corresponding to the
monomer subunit of the enzyme.  The gene has also been successfully cloned into a
pMT2 vector and transfected into COS-1 cells (163).  The cDNA from Saccharomyces
cerevisiae has also been cloned into a Yep13 plasmid and successfully transformed into
haploid Saccharomyces cerevisiae cells (164).  The cDNA from Pseudomonas putida has
also been isolated and cloned into a pBR322 vector plasmid that was utilized to transform
E. coli cells (165).  The amino acid sequences as well as the sequence of the
corresponding genes all exhibit strong regions of homology and are therefore likely
derived from a common ancestor.
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1.9       Glyoxalase II
Glo-II is one of at least three known thioesterases which are specific for
the GSH moiety.  Others include S-formylglutathione hydrolase (166) and
S-succinylglutathione hydrolase (167).  Both of these enzymes have been detected in the
liver (166) and red blood cells (167) of humans.  Studies have indicated that others may
occur in nature but the prevalence of these enzymes is as yet unknown.  Still, the most
prevalent GSH specific thioesterase known is Glo-II and it is therefore considered as the
model for thioesterase activity in living organisms.
1.9.1 Glyoxalase II – Assay of Activity
Glo-II activity may be assayed by following the decrease in absorbance at 240 nm
(ε = 3.37 mM-1 cm-1) due to the hydrolysis of the substrate, SLG (168).  A second widely
used method follows the production of GSH from the hydrolysis of SLG in the presence
of the thiol group reagent 5-5’ dithiobis(2-nitrobenzoic acid) (DTNB) at 412 nm
(ε = 13.6 mM-1 cm-1 ) (168).  Assays are conducted in an appropriate buffer at pH 7.4.
1.9.2 Glyoxalase II – Purification
A typical purification procedure for Glo-II usually begins with fractionation of
the cytosolic extract, followed by a variety of chromatography methods (168, 169).
Traditionally, fractionation was accomplished by the addition of ammonium sulfate;
presently, 70% acetone is more commonly used.  Chromatography steps generally
include any combination of anion and / or cation exchange, gel filtration, Affi-gel blue
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chromatography, hydroxyapatite, and a variety of GSH and GSH derivative affinity
chromatography matrices.  Until recently, multiple chromatography steps were required
to obtain an acceptable level of enzyme purity.
1.9.3 Glyoxalase II – Distribution
Glo-II activity has been found in all prokaryotic and eukaryotic tissues tested to
date, and it is therefore considered ubiquitous.  Glo-II activity has been detected in a
variety of mammals (168,169), a wide variety of vertebrates (170), yeast (171), bacteria
(172), helminthes (173, 174), protozoans (91), and fungi (175).  It has been purified from
a number of sources including human (168), mouse (176) and bovine (177) liver, as well
as from plants such as spinach (178), aloe vera (179), and corn (180).
Glo-II activity in mammals is not restricted to any particular tissue although
differences in specific activity from tissue to tissue have been reported (see Table III)
(37).  In humans, the greatest specific activity is found in the brain, with intermediate
levels of activity in the liver, kidney, muscle and heart, and very low activity occurring in
the spleen and pancreas.  In general, mammals exhibit the greatest Glo-II activity in the
liver and kidney, and the lowest degree of activity in the spleen.  Approximately 15% of
the Glo-II activity in a cell is found in the mitochondria, possibly the product of a
separate gene (39).  The mitochondrial enzyme has been reported to exist in both the
intermembrane space and the matrix (39).
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1.9.4 Glyoxalase II – Molecular Characteristics
The molecular characteristics of Glo-II from a number of sources are listed in
Table IV.  Glo-II is isolated as a monomer, although the existence of the enzyme in
multimer forms has been reported (181).  The molecular weight of the monomeric protein
ranges from 21 to 30 kDa, depending on the source.
Isozyme forms of Glo-II have been reported in a number of tissue types from a
number of organisms.  While only one form of the cytosolic enzyme was reported in both
human (168) and murine (176) liver, two forms were reported in rat liver (182).  Two
forms of the enzyme were reported in human erythrocytes (183) and rat brain (182) as
well.  In plants, three forms were reported in both aloe (179) and spinach (178), but only
one form was detected in corn (180).  The mitochondrial enzyme exists in five different
forms in the liver of both rat (39) and bovine calf (177), but only one form of the
mitochondrial enzyme was detected in spinach (175).
The isoelectric point of Glo-II is also dependent on the source.  The values for the
mammalian cytosolic enzyme are consistently in the basic region and range from pH
values of 7.4 to 8.5 (168, 169, 176, 181, 182).  The enzyme from plant (178-180),
bacterial (172), and fungal (175) sources exhibit isoelectric points only in the acidic
region ranging from a pH of 4 to 6.2.   The mitochondrial enzyme from rat (39) and
bovine (177) liver exhibit isoelectric points ranging from a pH of 6 to 8.
In the absence of crystallographic data, researchers have turned to methods such
as circular dichroic analysis, computer generated sequence analysis, and limited trypsin
digestion to gain information on the molecular organization of Glo-II (183).  Taken
together, the data predict that Glo-II is a typical α / β protein organized in two distinct
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domains.  The N-terminal region appears to be a highly compact, stable domain
consisting almost exclusively of beta-sheet.  The active site is thought to be present in
this domain.  The C-terminal region is predicted to exist almost exclusively as a flexible
α-helical domain void of, and non-essential for, catalytic activity.
1.9.5 Glyoxalase II – Substrate Specificity
The substrate specificity of Glo-II from a number of sources is summarized in
Table V.
With respect to the GSH moiety of the substrate, Glo-II is highly specific.
Neither the α-hydroxyesters of coenzyme A nor those of thioglycolate serve as substrates
for the enzyme (168).  The enzyme also exhibits no catalytic activity with substrates
containing oxygen esters (168).  As with Glo-I, the role of GSH in Glo-II activity is
thought to be restricted to enzyme recognition.
With respect to the carboxylic acid moiety of the substrate, Glo-II exhibits the
ability to accept a broad variety of acids as substrates (168, 184, 185).  As with Glo-I, the
ability to accept such a broad range of substrates is indicative of other detoxification
systems such as the cytochrome P-450 system (130) and GSH-S-transferase enzymes
(131).  The ability of the enzyme to accept substrates is not limited only to carboxylic
acids that possess a hydroxyl moiety on the C2 position.  This suggests that Glo-II
activity is not restricted to only the products of the Glo-I reaction, but may accept any
number of physiological substrates that possess the GSH ester linkage.
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1.9.6    Glyoxalase II – Kinetics
The Glo-II reaction appears to follow Michaelis-Menten kinetics over an
extensive range of substrate levels using SLG as a substrate (168).   SLG exhibits both a
relatively low KM value and the highest Vmax relative to other substrates tested (see
Table V) (168, 190).  This fact, coupled with the existence of a well-defined source of
SLG from the Glo-I reaction, has defined SLG as the physiological substrate for
Glo-II.  The KM values of Glo-II for this substrate consistently range from 0.14 – 0.22
mM (see Table III).  Exceptions to this are Glo-II derived from yeast, which exhibit KM
values of 7 µM for Saccharomyces cerevisiae (171) and 80 µM for Hansenula mrakii
(172).  The cytosolic enzyme from mammals consistently exhibits a specific activity of
600 – 900 µmol / min. / mg (see Table III).  Exceptions are values reported for the
cytosolic enzymes derived from yeast (1.34 µmol / min. / mg) (171), from corn (65 µmol
/ min. / mg) (180), and the mitochondrial enzyme from bovine calf liver (134 µmol / min.
/ mg) (177).
In vitro, quantitative kinetic models have predicted that the glyoxalase system can
act in a highly efficient manner in removing methylglyoxal from a cell (186).  Contrary to
these predictions, the catalytic efficiency of the glyoxalase system in vivo has been
predicted to be far less than that of the system when studied under such optimal in vitro
conditions (187, 188).
Quantitative kinetic models have led to the prediction that a purified preparation
of Glo-II is an efficient catalyst for the conversion of SLG to GSH and D-lactic acid
giving values for kcat / KM in the 10
5 – 106 range (189).  Under conditions in which the
rate of hydrolysis of SLG by Glo-II is determined at substrate concentrations << KM, the
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effect of increasing viscosity (using sucrose or glycerol) upon the kinetic parameters of
the Glo-II catalyzed reaction resulted in a significant decrease in the value of kcat / KM
(189).  This effect was demonstrated to be due to an increase in the KM for the substrate,
with no significant change in kcat being observed (189).  From these results, the reaction is
believed to be partially limited by diffusion and the rate of formation of GSH and D-
lactic acid from SLG by Glo-II was predicted to be as high as 50% of the theoretical
limits of diffusion  (189).  Therefore, the fate of the enzyme – substrate complex is
proposed to be distributed equally between the disassociation of the complex to reactants
and their conversion to products.
The value of kcat / KM is also highly dependent upon ionic strength when SLG is
used as a substrate (189).  Values were found to decrease significantly with increases in
ionic strength, an effect determined to be due to an increase in KM value (189).
Therefore, the encounter of substrate with enzyme is likely to be governed to some
degree by charge – charge interactions (189).
1.9.7 Glyoxalase II – Active Site Residues
Purified Glo-II from both human liver (168) and rat erythrocytes (184) is rapidly
inactivated by the amine reactive reagent, 2,4,6 trinitrobenzenesulphonate.  Protection
from inactivation by the competitive inhibitor, N-acetyl-S- (p-bromobenzyl) GSH was
observed for the enzyme from rat erythrocytes, suggesting the presence of an active site
amine.
Purified Glo-II from rat erythrocytes (184), liver and brain (182) is only partially
inactivated by the arginine – specific reagent, phenylglyoxal, at pH = 8.  Protection from
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inactivation in the presence of a competitive inhibitor was observed in all cases.  These
results suggest the presence of an arginine residue in the active site that is arguably
important in substrate binding.
Purified Glo-II from rat erythrocytes (184), liver and brain (182) is rapidly
inactivated by the histidine – specific reagent, diethylpyrocarbonate (DEPC) at a pH = 6.
With respect to the erythrocyte enzyme, protection from inactivation by a competitive
inhibitor was observed but reactivation by hydroxylamine, a reagent known to cleave the
DEPC – histidine adduct, could not be achieved (184).  With respect to the enzyme from
liver or brain, protection from inactivation by the slow substrate, S-mandeloylglutathione,
was observed (182).  In contrast to the enzyme from rat erythrocytes, reactivation of the
enzyme activity by hydroxylamine was achieved (182).  These results suggest the
presence of a critical active site histidine residue important in catalysis.
Purified Glo-II from rat erythrocytes (184) is not inactivated by the tyrosine -
specific reagent, tetranitromethane suggesting that a tyrosine residue is not involved in
catalysis. Purified Glo-II from rat erythrocytes (184), liver and brain (182) is also not
inactivated by the tryptophan – specific reagent, 2-hydroxy-5-nitrobenzylbromide
suggesting that a tryptophan residue is not involved in catalysis.
Diisopropylphosphofluoridate or phenylmethylsulfonylfluoride does not inactivate
purified Glo-II from rat erythrocytes (184), liver and brain (182).  Nor is the enzyme
inhibited by classical serine proteinase inhibitors such as leupeptin or chymostatin,
suggesting that a serine residue is not involved in catalysis and ruling out the possibility
of a serine-dependent thioesterase.
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The role of metal ions in Glo-II catalytic activity is unclear.  Previously,
experiments conducted on Glo-II from human liver (168) suggested that a metal ion is not
involved in the catalytic activity of the enzyme.  Short-term storage of the enzyme in the
presence of chelating agents such as EDTA, EGTA, and 8-hydroxyquinoline had no
effect on the activity of the enzyme.  On the other hand, long-term storage of the enzyme
with EDTA did cause complete labilization of the enzyme, with no reactivation being
observed after the addition of a variety of divalent ions.  Furthermore, Glo-II activity is
unaffected by phosphoamidon, a classical inhibitor of metalloproteinases.  Inactivation of
the purified enzyme from rat erythrocytes was observed during dialysis against EDTA,
1,10-phenanthroline, or 8-hydroxyquinoline-5-sulfonic acid, but again, no reactivation of
Glo-II activity was observed subsequent to the addition of a variety of metal ions (184).
These results were interpreted as suggesting that Glo-II is not a metallohydrolase.
Very recently one report suggests that Glo-II isolated from Arabidopsis thaliana
contains two moles of zinc atom per mole of enzyme (191).   It was also reported that this
metal ion is required for the activity and / or structural integrity of the enzyme.
Comparison of the amino acid sequence of this enzyme, as well as those from humans
and yeast has revealed a region of homology with that of the zinc-binding motif found in
metallo-β-lactamases.  Therefore the involvement of metal ions with respect to Glo-II
activity is now a topic of great interest in glyoxalase research.  Further study is warranted
to determine whether or not the zinc ions are involved directly with catalysis or if the ions
maintain the structural integrity of the enzyme, as is the case with Glo-I.
The role of cysteine residues in Glo-II catalytic activity is also unclear.  Uotila
(168) reported that the enzyme purified from human liver is quite unstable under a variety
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of storage conditions, and that activity could be stabilized only by the addition of rather
high concentrations of reducing agents such as mercaptoethanol (9.1 mM) and
dithiothreitol (5.5 mM).  In additional experiments, the enzyme was markedly inhibited
in a dose dependent manner by the addition of sulfhydryl group reagents such as HgCl2,
HgBzOH, 5-5’-dithiobis(2-nitrobenzoate) (DTNB), iodoacetate, and N-ethylmalemide
(NEM).  Uotila also reported the partial reactivation of the Hg-modified Glo-II activity
by the addition of dithiothreitol.  Supplementary studies showed that classical inhibitors
of cysteine – dependent hydrolases such as E64 and antipain were ineffective as Glo-II
inhibitors (168).
Further studies to determine the role of cysteine residues with respect to Glo-II
catalytic activity were conducted upon the purified enzyme from rat erythrocytes (184).
In this study, DTNB proved to be ineffective as an inhibitor of Glo-II, contrary to the
aforementioned experiments with the human liver enzyme.  Incubation of the enzyme in
the presence of NEM did cause partial inactivation of the enzyme, although the inhibition
reported may have been due to a loss of activity occurring during removal of the reagent
from the incubation.  No protection from inactivation of enzyme activity was observed
during incubation of the enzyme and NEM in the presence of a competitive inhibitor.
Further studies on the effect of NEM on the activity of both isoforms of Glo-II from the
liver and brain of Wistar rats gave similar results (182).
 Taken together, the effect of sulfhydryl group reagents on Glo-II activity all but
excludes the possibility of Glo-II being a cysteine-dependent hydrolase.  The partial
inactivation by NEM may be the result of a modification of a free cysteine residue.  Even
so, the presence of significant amounts of NEM in a Glo-II assay, a process dependent on
34
the reactivity of a sulfhydryl group reagent with free GSH, causes interference.
Therefore, removal of NEM previous to the assay is required.  Such a process may result
in loss of activity and therefore misinterpretation of the results.  The amino acid sequence
of human Glo-II identifies six cysteine residues, all of which are located in the N-
terminal region where the active site has been predicted to be located.  To date, no
information on the free sulfhydryl content of any form of Glo-II has been reported.
1.9.8    Glyoxalase II – Catalytic Mechanism
Results of the aforementioned chemical modification and inhibitor studies
exclude the possibility of Glo-II being a serine-dependent or cysteine dependent
hydrolase.  The assumption that a metal ion played no role in the hydrolytic activity of
Glo-II rules out the possibility of Glo-II being a metallohydrolase as well. A general acid
– general base mechanism of catalysis was also ruled out since studies with isotopic
water showed only a very small effect of the solvent isotope (184).  An E1cB mechanism
was ruled out as well, since S-α-deuterated substrates catalyzed by Glo-II did not exhibit
any loss of the deuterium by the products of the reaction (184).
Studies that identified an active site histidine in the enzyme that is essential for
catalysis, coupled with results from the aforementioned studies, have led to a proposed
histidine-dependent mechanism of Glo-II catalysis (184).  The mechanism proposes the
direct nucleophilic attack of the active site histidine on the thioester substrate.  This
proposal is supported by the known susceptibility of thioesters to aminolysis (192).
Predictably, the reaction would then proceed via the formation of an acyl-imidazole
intermediate, freeing GSH as a result of the reaction. The acyl-imidazole intermediate
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would then undergo rapid hydrolysis resulting in the release of the hydroxyacid to the
solvent.  This is consistent with the known lability of acyl-imidazoles (192).
 Although researchers for a number of years accepted the proposal for the
catalytic mechanism of Glo-II, recent advances in glyoxalase research have raised doubts
to its validity.  Recent reports have identified the presence of two moles of zinc per mole
of Glo-II enzyme purified from Arabidopsis thaliana (191). Comparison of the amino
acid sequence of this enzyme with those from humans and yeast has revealed a region of
homology with that of the zinc-binding motif found in metallo-β-lactamases.  Research is
ongoing to define the role of zinc with respect to Glo-II catalytic mechanism and / or
structural integrity.  The catalytic mechanism of metallo-β-lactamases is known to
proceed through an acyl-intermediate as well, although the residue acylated in the
lactamase reaction is a serine residue (193) while the proposed acylated residue in Glo-II
is histidine.
1.9.9    Glyoxalase II - Inhibitors
To date, the only natural metabolites that are known to inhibit Glo-II activity are
GSH (168) and the methylglyoxal – derived hemithioacetal substrate for Glo-I (24, 140,
171, 176).  The inhibition by GSH is quite weak, with the KI in the high millimolar range
(168).  The concentration of the hemithioacetal needed to provide a significant level of
Glo-II inhibition (Ki = 100-200 µM) is far above the predicted physiological
concentration of the hemithioacetal (194).  Therefore, the inhibition of Glo-II by these
compounds is not considered to be physiologically relevant.
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A number of substrate analog inhibitors derived from GSH have been
synthesized.  Among the most potent and specific of those inhibitors are thiocarbonate
derivatives and thiocarbonate / carbamate derivatives of GSH (180, 195-199).  These
inhibitors generally exhibit a high degree of specificity for Glo-II with Ki values in the
low micromolar range.  Table VI summarizes a number of Glo-II inhibitors developed to
date.
1.9.10 Glyoxalase II – Genetics and Cloning
In humans, the gene for Glo-II, HAGH, is located on chromosome 16, region
16p13.3 (200, 201).  Although humans are reported to express two forms of cytosolic
Glo-II, polymorphism is rare and has been reported only in Micronesian (200) and
Japanese (201) populations.  The more commonly expressed form of Glo-II, HAGH1, is
known to exist in two isoforms which may be separated by non-denaturing gel
electrophoresis (167).
A DNA fragment encoding Glo-II has been isolated from a human adult liver
cDNA library (202).  This DNA fragment consists of 1011 base pairs and a full-length
coding region of 780 base pairs, corresponding to a protein with a calculated molecular
mass of 28,861 daltons (202). A vector was successfully constructed for heterologous
expression of Glo-II in E. coli.
A cDNA encoding Glo-II from Arabidopsis thaliana has also been cloned and
sequenced (203).  It consisted of 894 base pairs and a full-length coding region of 774
base pairs, corresponding to a protein with a calculated molecular mass of 28,791 daltons
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(203). A vector was also successfully constructed for the heterologous expression of Glo-
II in E. coli.
Analysis of a T-DNA-tagged mutant of Arabidopsis thaliana has identified the
gene for, and has led to the isolation of, the cDNA of a Glo-II isozyme that appears to be
mitochondrially localized. The cDNA encoding a Glo-II cytoplasmic isozyme was also
isolated and characterized. Southern blot and sequence analyses indicate that the Glo-II
proteins are encoded by at least two multigene families in Arabidopsis thaliana. E. coli
cells expressing either form of the enzyme exhibit increased Glo-II activity, confirming
that they do encode Glo-II proteins. Northern analysis shows that the two genes are
differentially expressed, in that transcripts for the mitochondrial isozyme are most
abundant in roots, while those for the cytoplasmic isozyme are highest in flower buds.
The identification of Glo-II isozymes that are differentially expressed suggests that they
may play different roles in the cell.
Strong sequence homologies (50-60%) to the human liver Glo-II were found
within a limited region of GSH transferase I cDNA from corn (202).  The amino acid
sequence deduced from the A. thaliana cDNA showed 54% identity with that of the
human enzyme (203).  Databank searches identified seven additional DNA sequences
from different species with high similarity to Glo-II. Certain limited regions, one rich in
histidine residues, shared 100% identity (203).  Such data suggests that Glo-II from
different species may originate from a common ancestor and that other GSH requiring
enzymes may be related as well.
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1.10     Glyoxalase Activity - Proliferation, Differentiation, and Activation of Cells
Normal development in differentiating fetal tissues has been correlated with an
increased capacity to metabolize methylglyoxal.  It is accepted that the glyoxalase
phenotype is one of the earliest developed in fetal tissues.  In humans, the ability to
metabolize methylglyoxal exhibits full development before the end of the sixth week of
gestation and subsequently increases in activity until birth (205).  The increased ability to
metabolize methylglyoxal has been demonstrated to be due to a three-fold increase in
Glo-I activity in comparison to corresponding fully developed adult tissue.
Studies on developing chick embryos produced results similar to those obtained in
human fetal studies (206).  The livers of embryonic chicks exhibit a high level of Glo-I
activity but comparably low Glo-II activity during the process of differentiation before
hatching.  Furthermore, Glo-I activity decreased, while Glo-II activity increased, after
hatching.  The changes in glyoxalase activity under these conditions were not due to the
appearance of different isozymes during development.
The activities of the glyoxalase enzymes undergo changes during aging as well.
Studies on tissues from aged rats’ (214) and mice (105) were conducted to determine if
any changes in glyoxalase enzyme activity occurred in tissues due to aging.  In these
cases, the levels of both glyoxalase enzymes were greatly reduced in most tissues studied
relative to corresponding tissues from younger subjects.
Other studies have been conducted on regenerating liver tissue to determine the
status of the glyoxalase system in rapidly proliferating tissues.  Regeneration of liver
tissue has been induced by partial hepatectomy (104), radiation damage (208), or the
addition of carcinogens to the diet; conditions that result in an uncontrolled state of
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proliferation (209). In all cases, a significant increase in the activity of Glo-I and a
correlative decrease in the activity of Glo-II occurred.  Other studies in which the
glyoxalase activity of rapidly proliferating tumor cells were compared to that of normal
corresponding tissues (210, 211) demonstrated high Glo-I activity, whereas Glo-II
activity was either undetectable or at least greatly reduced.
The activation of resting blood cells such as platelets causes significant changes in
the ability of these cells to metabolize methylglyoxal.  Resting platelets completely
metabolize methylglyoxal to lactate, while stimulated platelets transform only 10 – 15 %
of the α-ketoaldehyde to lactate (212).  The stimulation of these cells by agonists, in
particular thrombin, was later demonstrated to result in the accumulation of SLG in a
dose dependent manner (213), suggesting the inhibition of the Glo-II reaction.  The
addition of methylglyoxal to platelets in vitro has been demonstrated to produce an
oxidative effect resulting in an increase in hydrogen peroxide, an increase that is
potentiated by thrombin stimulation (212).  Furthermore, the addition of methylglyoxal to
platelets in vitro inhibits both the agonist-induced aggregation of platelets as well as the
release of ATP from platelets (212).
Further studies have also been conducted on the status of the glyoxalase system
during the functional activation of both human polymorphonuclear leukocytes (22) and
resting neutrophils (72, 73).  Both human polymorphonuclear leukocytes and resting
neutrophils, when stimulated by phorbol ester treatment, in culture, demonstrated a
significant increase in Glo-I activity.  This increase was proposed to be due to a
significant increase in the maximum velocity of the enzyme (187).  Glo-II activity
decreased after stimulation, and was proposed to be due to a significant decrease in the
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maximum velocity of the enzyme (187).  Since the Michaelis constants for both enzymes
did not undergo any change during stimulation, it was suggested that the stimulatory
process caused the appearance of an unidentified non-competitive binding constituent
that affected glyoxalase activity.
Studies have been conducted on the status of the glyoxalase system in
differentiating blood cells (207).  Both human promeolytic leukemia (HL60) cells and
erythroleukemia cells in culture exhibited high Glo-I activity and low Glo-II activity prior
to differentiation.  The chemically induced differentiation of these cells resulted in a
significant loss of Glo-I activity; this was later shown to be due to a significant decrease
in the maximum velocity of the Glo-I activity (187).  These cells also exhibited an
increase in Glo-II activity after differentiation, suggesting (to the investigators) a
significant increase in the maximum velocity of the Glo-II activity of the cytosolic extract
(187).  Since the Michaelis constants for both enzymes under these conditions did not
undergo any change during differentiation, results were again related to the existence of
an unidentified non-competitive binding constituent that affected glyoxalase activity.
The decrease in the ratio of Glo-I / Glo-II activity in differentiating blood cells is in
contrast to the increase in the ratio of Glo-I / Glo-II activity in blood cells which have
been by activated from the resting state by chemically - induced stimulation.
Overall, glyoxalase activity appears to undergo changes as the physiological state
of the cell changes with respect to proliferation, differentiation, and activation.  Rapidly
proliferating cells appear to exhibit a consistent and significant increase in the ratio of
Glo-I / Glo-II activity when compared to corresponding quiescent tissues.  Upon
activation, blood cells such as platelets, leukocytes, and neutrophils appear to undergo
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similar increases in the Glo-I / Glo-II ratio when compared to corresponding cells in a
resting state.  In contrast, differentiating blood cells appear to exhibit a decrease in the
ratio of Glo-I / Glo-II activity.  Limited evidence has led to the proposal of the existence
of a metabolite that affects glyoxalase activity in a non-competitive manner.
1.11     Glyoxalase Activity – Relationship to Glucose Metabolism
Although any direct relationship between the glyoxalase system and the glycolytic
pathway had been discounted, flux through the glyoxalase pathway as well as the fate of
glyoxalase metabolites appears to be indirectly affected by the state of glucose
metabolism in an organism.
Studies involving the stimulation of glucose metabolism by way of anaerobic
exercise in humans demonstrated a decrease in methylglyoxal concentrations with a
corresponding increase in D-lactate levels in both plasma and red blood cells (81).  These
results were interpreted as indicating that an increase in glucose metabolism stimulates an
increase in the flux through the glyoxalase pathway.  Since the levels of D-lactate in
excretory fluids (urine and sweat) were unchanged, it was assumed that the body in some
other process utilized the D-lactate.
In other studies designed to determine the relationship of the glyoxalase system to
glucose metabolism, methylglyoxal was shown to be a gluconeogenic precursor in rats
who had been starved under a variety of conditions (215), a process that had been later
suggested to be calcium dependent (216).  It is possible that methylglyoxal could enter
the gluconeogenic pathway at the position of pyruvate, either by the oxidation of
methylglyoxal directly to pyruvate by methylglyoxal dehydrogenase (E.C.  1.2.1.23)
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(48, 49), or by the conversion of D-lactate to pyruvate by 2-hydroxyacid dehydrogenase
(79).  Even so, the inhibition of glyceraldehyde-3-phosphate dehydrogenase did not affect
the flux of methylglyoxal to glucose in isolated murine hepatocytes; this was interpreted
as indicating the existence of an alternative pathway from methylglyoxal to glucose
(217).
Studies involving the fate of methylglyoxal in human diabetic subjects also
indicate that the flux through the glyoxalase pathway appears to be indirectly affected by
the state of glucose metabolism in an organism.  Isolated red blood cells from normal
humans cultured under hyperglycemic conditions demonstrated an increased flux of
methylglyoxal to D-lactate with no detectable corresponding changes in enzyme activity
(218).  In another study, the levels of methylglyoxal, SLG, and D-lactate were all
demonstrated to increase in the blood samples of diabetic patients, indicating an increase
in flux through the pathway (219).
Studies comparing normal rats to streptozotocin-induced diabetic rats
(a model for insulin dependent diabetes) have provided further support that flux through
the glyoxalase pathway is affected by the state of glucose metabolism in an organism
(82, 220).  Glycolytic tissues (lens and blood) demonstrated increased concentrations of
both methylglyoxal and D-lactate in diabetic rats when compared to controls (82).  Insulin
dependent tissue (skeletal muscle) exhibited a decrease in methylglyoxal concentration
with a corresponding increase in the concentration of D-lactate in diabetic rats when
compared to controls (82). In gluconeogenic tissue (liver), the concentration of
methylglyoxal was also decreased with a corresponding increase in the concentration of
D-lactate (82).  In another study involving the same model, glyoxalase enzyme activity
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increased in its capacity to metabolize methylglyoxal in skeletal muscle (220).  In
contrast to skeletal muscle, glyoxalase enzyme activity in the liver was decreased in its
capacity to metabolize methylglyoxal (220).
Studies using the obese diabetic rat (a model for non-insulin dependent diabetes)
have provided further support that flux through the glyoxalase pathway is affected by the
state of glucose metabolism in an organism (82).  An overall increase in the conversion of
methylglyoxal to D-lactate was demonstrated in the tissues of these subjects.
Furthermore, the concentration of methylglyoxal increased in blood samples, but also
decreased in both muscle and liver.  These results parallel those in studies on the
streptozotocin-induced diabetic rat.
It should be noted that glycerol was demonstrated to be the best substrate tested as
a carbon source for the formation of D-lactate, followed by glucose, in both the cytosolic
fraction of rat liver as well as that of perfused rat liver (221).  It is well documented that
the levels of both glycerol kinase (82) and hepatic glycerol (221) increase dramatically
under diabetic conditions in these same subjects.
Overall, evidence indicates that the flux through the glyoxalase system is
indirectly affected by the state of glucose metabolism in an organism. Predictably, in an
organism where a normally functioning glyoxalase system is operating, the steady state
levels of methylglyoxal found in tissues are predictably too low to cause significant
damage to an organism.  Therefore, damage due to toxic methylglyoxal may occur only
when the physiological balance of the organism is disrupted, resulting in a chronic
increase in the levels of toxins such as methylglyoxal.  Diabetes is a plausible example of
such disruption and the effect of chronic increases in the level of methylglyoxal in
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diabetic subjects has become the topic of increased interest.  Current research topics
include the formation of advanced glycosylation endproducts (AGE proteins) (66-68) and
the development of diabetic complications such as cataract formation (65), as well as the
modification of connective tissue proteins (222).
1.12     Background to the Present Work
1.12.1  Rate of Flux through the Glyoxalase System
As stated earlier, changes in either the proliferative state (in particular cancerous
tissue) or changes in the state of glucose metabolism (in particular in diabetic patients) in
any given tissue also causes changes in the flux of methylglyoxal to D-lactate through the
glyoxalase system.  It is due to these findings that a renewed interest in the glyoxalase
system has occurred.  This system is regarded as a possible target in both anticancer
therapies and the alleviation of diabetic complications.  Therefore, studies that provide a
clear understanding of the mechanism by which the glyoxalase system undergoes such
changes in flux is, obviously, well timed.
Although the activity of the glyoxalase enzymes has been demonstrated to
undergo changes under the aforementioned conditions, no definitive evidence for
allosteric control or control of flux by way of induction of the glyoxalase enzymes exists
to date.  Researchers have therefore begun to rely upon the comparison of data derived
from quantitative kinetic models to that of in vivo experiments to develop a more clear
understanding of the factors that may control the kinetic properties of the glyoxalase
system inside cells.
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In order to ascertain the efficiency of the glyoxalase system in the removal of
methylglyoxal from cells, as well as determine if any unknown kinetic factors are
involved in the conversion of methylglyoxal to D-lactate, quantitative models of the
pathway have been developed (186, 189, 223). To date, all studies indicate that the steady
state concentrations of the substrates for the glyoxalase enzymes in vivo are maintained at
subsaturating levels (<< KM values reported for that enzyme) (110, 186, 187, 189, 223).
Therefore, results from in vitro studies have been used to propose a model for the
metabolic flux through the system under conditions in which substrate concentrations are
much lower than the KM values for the two enzymes (186, 189, 223).
Under these conditions, the overall rate of the conversion of methylglyoxal to D-
lactic acid is thought to be limited by the rate of formation of the hemithioacetal substrate
for Glo-I (186).  This interpretation was obtained from calculations based upon free
energy diagrams derived from apparent rate constants for each of the reactions that occur
within the glyoxalase system (186).  The concentration of GSH in tissues is generally
maintained at concentrations high enough to be kinetically unimportant in the reaction
(186).  Therefore, the formation of the hemithioacetal is then predicted to be dependent
upon the concentration of free methylglyoxal; the flux through the system is thus under
substrate level control.
Both of the glyoxalase enzymes in their purified state appear to act at near optimal
catalytic efficiency (189, 223).  Values for kcat / KM
(3.5 ∗ 106 M-1 s-1 for yeast Glo-I, 8.8 ∗ 105 M-1 s-1 for rat erythrocyte Glo-II, at pH 7,
25°C) approach the estimated upper limits for such values (224).  By the application of
the viscogenic variation method to kinetic studies, both enzymes have been demonstrated
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to be approximately 50% limited by the rate constant for the diffusion controlled
encounter between the active site of the enzyme and the substrate (k1) under conditions
where substrate concentrations are << KM (189, 223).  Thus, in the purified state, both of
the glyoxalase enzymes are significantly diffusion-limited and therefore seem to have
evolved to a high level of catalytic efficiency.
Whether or not the activities of the glyoxalase enzymes are diffusion limited
inside the cell is still in question.  If the quantitative kinetic model of the glyoxalase
pathway is correct, the concentration of the pathway intermediates can be estimated from
the net production of D-lactate in any given tissue and the intracellular concentrations of
the glyoxalase enzymes (223).  Using this kinetic model, the steady state concentrations
of the intermediates were estimated to be 0.7 ± 0.1 nm for the methylglyoxal-derived
hemithioacetal and 1.9 ± 0.5 nM for SLG (223).
Contrary to these estimates, the concentrations of the intermediates of the
glyoxalase system in human erythrocytes have been reported as exceeding the calculated
steady state concentrations by orders of magnitude (0.8 ± 0.14 µM for the hemithioacetal,
14.9 ± 4.6 µM for SLG) (110, 187).  The difference between the estimated concentrations
of the pathway intermediates in kinetic models and tissue studies led to the proposal of
the existence of an as yet unidentified inhibitor of glyoxalase activity, resulting in the
unexpected high steady state concentrations of the pathway intermediates (110, 187,
223).  This proposal was further supported by experiments that detected approximately
104 – fold increases in Glo-II activity in red blood cells upon cell lysis (110).  In those
cases studied to date, the intracellular activities of other non-allosteric, water-soluble
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enzymes, the activities are unchanged upon cell lysis (225, 226).  Further, no effective
physiological inhibitor of glyoxalase activity has been identified.
Faced with this discrepancy, researchers have turned to alternative explanations for
the unexpected high concentrations of glyoxalase pathway intermediates.  The
discrepancies may be, in part, attributed to the reliability of the assay systems used.
Thus, the increase in methylglyoxal / hemithioacetal concentrations could be, in part, due
to aberrant sources of methylglyoxal arising from the buffer-ion catalyzed decomposition
of trioses and triosephosphates in biological extracts (32).  This proposal does not explain
the higher than expected intracellular concentrations of SLG.  Only a small percentage of
the discrepancy in these estimates has been demonstrated to result from either the acid-
catalyzed esterification of GSH by L-lactate during the acid denaturing of whole blood
samples (227) or the overestimation of SLG concentrations due to the presence of both
the D and L isomers of the intermediate (228).
A second explanation for the discrepancies in the concentrations of glyoxalase
pathway intermediates is that the small steady state concentrations estimated from the
quantitative models are in equilibrium with much larger pools of these intermediates that
are reversibly bound to intracellular proteins (223). The higher methylglyoxal /
hemithioacetal concentrations has been demonstrated to be, in part, due to the reversible
binding of methylglyoxal to proteins, particularly cysteine, arginine, and lysine residues
(229).  Again, this does not explain the increase in intracellular concentrations of SLG.
To date, no evidence for the existence of an intracellular pool of reversibly bound SLG
exists.  Therefore, although the unexpected increases in the intracellular concentrations of
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the methylglyoxal / hemithioacetal intermediates in cells may have been accounted for,
no explanation for the high concentrations of the substrate for Glo-II, SLG, exists to date.
1.13.2 Inhibition of Glo-II Activity by Purine Nucleotides
Some years ago, it was observed in this laboratory that the Glo-II activity of a
crude cytosolic extract of rat liver is significantly inhibited when assayed in the presence
of ATP or GTP (0.3 – 1.0 mM).  Recently, we have conducted a limited nucleotide
inhibition survey of plant and bacterial cell free extracts, as well as the cell free extracts
from various organs from a number of animal species.  We have found that ATP and
GTP typically inhibit the Glo-II thiohydrolase activity of those cytosolic extracts from
plant and animal species.  On the other hand, ATP or GTP did not significantly inhibit
Glo-II activity in cytosolic extracts of Escherichia coli.  Table VII summarizes these
results.
Although the inhibition of Glo-II activity by ATP or GTP is observed in the cell
free extracts of all higher animals and plants tested, it was also found that Glo-II, purified
by traditional methodologies, is no longer inhibited by ATP or GTP.  The loss of
nucleotide sensitivity during the purification process was at first thought to be due to the
removal of some unidentified factor during the purification.  Since studies to identify
such a factor were unsuccessful, it became apparent that the sensitivity of thioesterase
activity to ATP or GTP must be an intrinsic characteristic of the enzyme itself.
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1.12.2 Hypothesis and Objectives
The central hypothesis of this work is that Glo-II can exist in two forms, one of
which is sensitive to inhibition by certain nucleotides while the other is not.  The purpose
of this work is to provide the tools needed for the purification and characterization of
each of these forms of Glo-II.
Objective 1; Purification of Glo-II-s
Studies were initiated to determine if an enzyme purification procedure could be
developed such that the pure enzyme retains its sensitivity to inhibition by nucleotides.
Purification processes reported in literature for the preparation of homogenous Glo-II
employ several fractionation steps, and require days to complete (168, 169).  ATP or
GTP does not significantly inhibit pure preparations of Glo-II obtained by such
procedures.
As the following objectives were dependent upon the success of the first
objective, in our earlier studies we had developed a rapid, one-step affinity
chromatography method to purify bovine liver Glo-II from cytosolic fractions.  The Glo-
II activity purified under these conditions is significantly inhibited when assayed in the
presence of ATP or GTP.  For convenience, we have designated Glo-II activity that is
significantly inhibited by physiological levels of ATP as “sensitive Glo-II” (Glo-II-s).
We have designated Glo-II activity that is not significantly inhibited by physiological
levels of ATP as “insensitive Glo-II” (Glo-II-i).  Only one reference, originating from
work in our laboratory, refers to the inhibition of Glo-II activity by nucleotides (25).
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Objective 2; Determination of the inhibition properties of Glo-II-s.
In order to set the experimental parameters to be used in subsequent studies, the
stability of Glo-II-s with respect to temperature and pH were to be determined.  Once this
step was completed, a survey was to be conducted to determine which nucleotides inhibit
Glo-II-s, and of these, which ones are most inhibitory.  Once these investigations were
completed, the kinetic parameters of Glo-II-s and the type of inhibition by nucleotides
were to be determined.
Objective 3; Investigation of the conditions which result in the loss of nucleotide
inhibition by Glo-II-s
In our initial studies, we have observed the gradual loss of nucleotide sensitivity
by Glo-II-s after purification.  Standardized conditions, which cause the loss of
nucleotide sensitivity by Glo-II-s in a reasonable time period, were to be determined.
Such conditions would allow for a repeatable laboratory process for the acquisition of the
resultant Glo-II-i for further study.
In other early studies, we have observed the rapid loss of nucleotide sensitivity of
Glo-II-s by short-term incubation with certain inhibitory nucleotides.  Further
investigations of this observation were also to be conducted in order to determine if these
conditions also cause the transition from Glo-II-s to Glo-II-i.
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Objective 4; Determination of the kinetic properties of Glo-II-i.
Once standardized, repeatable conditions for the transition of Glo-II-s to Glo-II-i
were found, the kinetic parameters of Glo-II-i were to be determined and compared to
those of Glo-II-s.
Objective 5 – Investigation of the structural / conformational differences between
Glo-II-s and Glo-II-i.
A number of biochemical studies were to be conducted in order to investigate any
structural / conformational differences in the protein that occur upon the transition of
Glo-II-s to Glo-II-i.  Studies were to determine if the transition is due to:
1. a change in the molecular weight of the enzyme (as determined by SDS-PAGE),
2. a change in the molecular shape (conformation) of the enzyme, or the formation
of multimer forms of Glo-II (as determined by gel-filtration), and
3. a change in the structural conformation of the enzyme (as determined by circular
dichroic analysis and / or tryptophan fluorescence).
Objective 6; Chemical modification studies on Glo-II-s
A series of chemical modification studies were to be conducted on samples of
Glo-II-s in order to investigate the effect of modification on both the activity and
inhibition of Glo-II activity by nucleotides.  Results from this study will be compared to






Affi-gel-10 affinity chromatography material was purchased from Bio-Rad.  DTA was
purchased from U.S. Biochemical.  All other chemicals were purchased from Sigma.  All
solvents used were of reagent grade.
Methods
Synthesis of Affi-gel 10-glutathione (Af-SG) Affinity Chromatography Matrix
The Af-SG material, in which the sulfhydryl group links the GSH to the matrix,
was synthesized by the method of Norton et al (180) with modifications.  First, GSH, 350
mg, was dissolved in 50 mL of ice cold sodium acetate, 30 mM, pH 5.5.  The pH was
then adjusted to 5.0 with a 10% sodium hydroxide solution.  Second, a wet volume of 25
mL of Affi-gel 10 was washed with 5 volumes of ice cold sodium acetate buffer, 30 mM,
pH 5.5.  Third, the washed Affigel –10 was added to the GSH solution and gently shaken
overnight at 4°C.  Finally, the resulting solid Af-SG material was washed with 10
volumes of 50 mM TRIS buffer, pH 7.4 to remove excess GSH.  The resulting
suspension was utilized in the affinity chromatography step in the purification of Glo-II.
Abbreviations: SLG: s-D-lactoylglutathione, GSH: glutathione, DiFMOC-G: N,S-
bisflourenylmethoxycarbonyl-glutathione, DEPC: diethylpyrocarbonate, EDTA: ethylenediamine
tetraacetic acid, NEM: N-ethylmalimide, DMSO: dimethylsulfoxide, PMSF: phenylmethylsulfonyl
fluoride, DTT: dithiothreitol, GSSG: glutathione (oxidized), DTA:  meso-2,5-dimercapto-N,N,N’,N’-
tetramethly-adipamide, ApppA: diadenosine triphosphate, PolyA: polyadenylic acid, DTNB: dithiobis-
nitrobenzoic acid, EGTA: ethylene glycol-bis (β-aminoethyl ether)N,N,N’,N’-tetraacetic acid, TRIS:
tris[hydroxymethyl]aminomethane, TES: N-trsi[hydroxymethyl]methyl-2-aminomethanesulfonic acid.
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Preparation of Di-FMOC-G Solution
The Di-FMOC-G solution was prepared by dissolving 10 mg DiFMOC-G,
sodium salt, in 0.5 mL of DMSO with vigorous shaking.  The resulting solution was then
added to 9.5 mL of 100 mM TRIS, pH 7.4, at room temperature with vigorous shaking.
After cooling to 5°C, any turbidity was removed using a 0.45 µm filter.
Preparation of the Cytosolic Fraction from Calf Liver Tissue Homogenate
Livers were obtained from healthy bovine calves at the time of death and stored in
saline ice water slurry during an average transport period of 1 hr..  All further steps were
carried out without delay at 0-4°C with 100 mM TES buffer, pH 7.4 (buffer A) unless
otherwise stated.  The tissue was homogenized with 1 volume of buffer A, containing 100
µM PMSF, for 1 min. using a household blender at low speed.  To this homogenate was
added a solution of two volumes of buffer A and 1 volume of glycerol and the resulting
mixture was blended at high speed for two, 1 min. intervals.  The homogenate was then
filtered through sterile gauze and centrifuged at 14,000 x g for 1 hour at 5°C.  The pellet
was discarded.  The supernatant solution was recovered and used in further purification
steps.
Acetone Fractionation of the Cytosolic Fraction from Calf Liver Tissue Homogenate
Three volumes of cold acetone (-20°C) were added slowly to the cytosolic
fraction from calf liver tissue homogenate with gentle mixing and stirred for 30 min. at
1°C.  The solution was then centrifuged at 14,000 x g for 10 min. at 5°C.  The
supernatant solution was discarded.  The pellet was dissolved into one volume of buffer
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A by gentle stirring for 1 hr. at 4oC and then centrifuged at 14,000 x g, 5°C, for 2 hr..
The resulting pellet was discarded.  The supernatant solution (acetone fraction) was
recovered and used in further purification steps.
Purification of Glo-II by Af-SG Affinity Chromatography
All steps were conducted at 4°C at a pH of 7.4 unless otherwise stated.  GSH-
Affigel-10 was added to a small column (1 x 1 cm. gel bed volume), and equilibrated
with 100 mL buffer A.  The acetone fraction (200 mL) was passed through the column, at
a flow rate of approximately 100 mL / hour.  Fractions (0.25 ml) were collected from the
column and assayed periodically until saturation of the column had occurred.  Non-
specifically bound protein was then removed from the column by washing with 100 mL
of buffer A, followed by 50 mL of 150 mM TES, pH 7.4, followed by 10 mL of 200 mM
TES, pH 7.4, and finally 10 mL of buffer A.
Elution of the enzyme was carried out with a 0.5 mM solution of DiFMOC-G, 10
mL, at a flow rate of 5 mL/min.  Typically, elution was complete with the application of
about 5 mL of elutant.  The eluate obtained from the column was incubated at 5°C for 1
hr. to allow for hydrolysis of the Di-FMOC-G by the Glo-II activity.  Then, four volumes
of cold acetone (-20°C) were added, and the solution was incubated at -20°C for 5 hr.
The sample was then centrifuged at 16000 g, 5°C, for 1 hr..  The supernatant solution was
removed and the pellet (pure Glo-II) was dissolved in 1 mL of buffer A.  The resulting
sample was typically apportioned into 20 Eppendorf tubes (50 uL / tube), and stored at
80°C until use.
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Protein Determination of Purified Glo-II Preparations
Protein determinations were carried out according to the method of Bradford
(230) using a protein determination kit purchased from Sigma, bovine serum albumin as a
standard, and procedures as set by the manufacturer.
Determination of Molecular Weight and Analysis of Purity of Glo-II Preparations
Analysis of the purity of Glo-II preparations was carried out by sodium dodecyl–
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) by the method of Laemmli
(231).  Electrophoresis was conducted using a Bio-Rad mini-gel apparatus, with a 3%
acrylamide stacking gel and a 15% acrylamide resolving gel, according to the
manufacturer’s specifications.  Determination of the molecular weight of the enzyme was
done by comparison of the relative mobility of the protein to those of a set of low
molecular weight standards purchased from Sigma and treated according to the
manufacturers specifications.  Detection of the protein was conducted by utilizing both
Coomassie blue (232) and silver staining (233).
Synthesis and Standardization of SLG
SLG was prepared and purified according to the method of Uotila (234). Stock
solutions of SLG (50 mM) were made up in distilled water and their concentrations were
standardized by enzymatic endpoint assay (extinction coefficient = 13600 M -1 cm –1 at
412 nm) which involves the hydrolysis of SLG to D-lactate and reduced GSH in the
presence of DTNB when catalyzed by the addition of Glo-II.
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Standardization of Nucleotide Solutions
 Nucleotide stock solutions were made up in distilled water and their
concentrations were determined by UV spectroscopy using previously published
extinction coefficients (235).
Routine Glo-II Assay
Glo-II activity was measured by following the increase in absorbance at 412 nm
(extinction coefficient = 13.6 mM-1 cm-1) due to formation of the chromophoric adduct
between 5-5’dithiobis(2-nitrobenzoic acid) (DTNB) and the free, reduced GSH released
from the enzymatic hydrolysis of the thioester, SLG.  A typical assay mixture contained
0.2 mM DTNB, 0.25 mM SLG, and 0.01 to 0.04 units of enzyme solution per mL of
assay mixture in buffer A, at 25°C.  The reaction, which was initiated by the addition of
enzyme, unless otherwise stated, was followed for 1.5 min. on a Shimadzu UV-VIS
spectrophotometer, model 1201, equipped with a kinetic software program.  Initial rates
were determined from the slope of the linear plot generated by the increasing absorbance
from the chromophore formation.  A blank without enzyme was always included.  One
enzyme unit is defined as the amount of enzyme (Glo-II) required to convert 1 µmol of
SLG to GSH and D-lactate at 25°C per minute under the assay conditions described.
Temperature Stability Studies on Glo-II-s
Aliquots of purified Glo-II-s (2.5 U / mL) were incubated at various temperatures
and aliquots were removed, diluted, and assayed periodically for activity.  All assays
were conducted as described above at a SLG concentration of 0.25 mM.
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Studies of the Effect of pH on the Stability of Purified Glo-II-s
Aliquots of Glo-II-s (2.5 U / mL) were incubated at various pH values for five
min. on ice.  The incubation buffer used contained 40 mM citrate, 40 mM TES, 40 mM
TRIS, adjusted to specific pH values ranging from 4-10.  Aliquots of the enzyme
incubation were removed at designated time intervals, diluted 20-fold into buffer A, and
assayed for activity in the usual assay buffer.  Data were recorded as the percent activity
relative to a fresh, 20-fold dilution of the enzyme in which the pH had not been altered.
The SLG concentration in the assay was 0.25 mM.
Studies of the Effect of pH on Glo-II-s, Activity and Nucleotide Inhibition
Glo-II-s was incubated at a variety of pH values (5.5-8.5) in a buffer containing
40 mM citrate, 40 mM TES, 40 mM TRIS, 0.4 mM SLG for 1 minute at 25°C in a final
volume of 1.0 mL.  The reaction was started by the addition of substrate.  The reaction
was then quenched by the addition of 300 uL of 1N HCl.  After a five minute incubation
under these conditions, to ensure irreversible enzyme denaturation, the pH of the
solutions were brought to pH 7.4 by the addition of 2.7 mL of a 1 M TES buffer at pH
7.4, containing 0.8 mM DTNB.  For all samples a blank with no enzyme present was
treated similarly.  The absorbance of each sample was then read at 412 nm against the
appropriate blank.  The experiments were also conducted in the presence of 2 mM ATP.
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Inhibition Studies with Nucleotides
Glo-II-s was assayed in the presence of various nucleotides to determine which of
them were inhibitory.  The nucleotides tested included ATP, ADP, AMP, GTP, GDP,
GMP, CTP, UTP, ITP, IMP, NAD, NADH, NADP, NADPH, FMN, pppGpp, ppGpp,
ApppA, ADPR, and PolyA.  Nucleotide solutions were prepared as previously described
and the final concentration in the assay was 2 mM.  The assays were also conducted as
previously described at a SLG concentration of 0.25 mM.
Incubation Studies with Nucleotides
Nucleotides tested were ATP, ADP, AMP, GTP, GDP, GMP, and UTP. Samples
of concentrated Glo-II-s (20 U.) were incubated for 1 hour at 12OC in the presence of
nucleotide (1.4 mM).  Samples were then diluted (1:500) into the assay medium such that
residual nucleotide concentration from the incubation was 2.8 µM (a non-inhibitory
concentration).  All samples were then assayed as previously described at a SLG
concentration of 0.25 mM.  A control, in which no nucleotide had been added, was also
included.
Kinetic and Inhibition Studies
Lineweaver-Burk plots were constructed from the experimental data.  Final SLG
concentrations in the kinetic assays ranged from 0.075 – 1.000 mM.  Final nucleotide
concentrations in the kinetic studies ranged from 0.0 –1.0 mM.  Graphical representation
of the data was completed using a Microsoft Excel software program, Version 8.0a.
Lines were drawn using linear regression.  Replots of the calculated data were
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constructed from the corresponding Lineweaver-Burk data and lines were drawn using
either linear or polynomial regression programs.
In assays designed to determine the percent inhibition of Glo-II by ATP, the SLG
concentration in all assays was 0.25 mM.  ATP concentrations in the assays ranged from
0-10 mM.   The values of the percent inhibition of Glo-II activity at constant SLG
concentration and increasing ATP concentrations were calculated from the ratio of the
inhibited rate to the uninhibited rate. Graphical representation of the percent inhibition
data was completed using a Microsoft Excel, Version 8.0a program.  Lines were drawn
using polynomial regression.
Conversion of Glo-II-s to Glo-II-i at 12°C
Glo-II-s (2.5 U / mL) was incubated at 120C and aliquots were removed at
designated time intervals, diluted, and assayed for activity.  Assays were conducted in the
absence and in the presence of 2 mM ATP as earlier described.  The SLG concentration
in the assay was 0.25 mM.  Data were recorded as the percent residual Glo-II activity and
as the percent residual inhibition of Glo-II by ATP, as compared to initial values (zero
time incubation).
Conversion of Glo-II-s to Glo-II-i by Incubation with ATP
Samples of concentrated Glo-II-s  (20 U / mL) were incubated for 2 hr. at 1OC in
the presence of 5 mM ATP.  At designated times during the 2 hour period, aliquots were
removed and diluted into the assay medium such that the residual nucleotide
concentration in the incubation mixture was 6 µM (a non-inhibitory concentration).
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Controls with no ATP present were treated similarly.   After dilution, samples were
assayed at 0.25 mM SLG to determine any changes in activity.  Samples were also
assayed at 0.25 mM SLG in the presence of 2 mM ATP to determine any change in the
inhibition of Glo-II activity by this nucleotide.
Chemical Modification Studies with Glo-II-s
Chemical modification of histidine residues by incubation with the histidine-
specific reagent, diethylpyrocarbonate (DEPC), was done at 1°C using 1-4 U  of Glo-II-s
in 30 mM MES, pH 6.0.  The modification reaction was started by the addition of an
aliquot of a DEPC / EtOH stock solution (1% EtOH, 6 mM DEPC final concentration in
the incubation).  Aliquots were removed at appropriate time intervals and assays were
conducted as previously described without and without 2 mM ATP.  A control with no
reagent added was treated similarly.
Chemical modification of arginine residues by incubation with phenylglyoxal was
done at  1°C using 1-4 U  of Glo-II-s in 100 mM TRIS, pH 7.7.  The modification
reaction was started by the addition an aliquot of phenylglyoxal / DMSO stock solution
(5% DMSO, 5 mM phenylglyoxal final concentration).  Aliquots were removed and
assays were conducted as previously described, without and without 2 mM ATP.  A
control with no reagent added was treated similarly.
Chemical modification of serine residues by incubation with PMSF was done at
1°C using 1-4 U of Glo-II-s in 100 mM TRIS, pH 7.4.  The modification reaction was
started by the addition of an aliquot of PMSF/EtOH stock solution (2 mM PMSF final
concentration).  Aliquots were removed and assays were conducted as previously
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described, with and without 2 mM ATP.  A control with no reagent added was treated
similarly.
Studies on the effect chelation agents, such as EDTA and EGTA, were done at
1°C using 1-4 U of Glo-II-s in buffer A.  The incubation was started by the addition an
aliquot of a stock solution of chelation reagent (2 mM final concentration).  Aliquots
were removed and assays were conducted as previously described, with and without 2
mM ATP. A control with no reagent added was treated similarly.
Chemical modification of sulfhydryl residues was carried out at 1°C in buffer A.
Concentrated solutions of Glo-II-s (50 U / mL) were incubated under these conditions in
the presence of 5 mM DTNB, NEM, GSH, DTA, GSSG, H2O2, and Diamide for 200
min..  A control containing no sulfhydryl group reagent was incubated similarly.
Aliquots were removed from the incubations at zero time, diluted 1,250 fold, and assayed
in the presence and absence of 2 mM ATP. At the end of the 200 minute incubation
period, all samples were diluted as above and assayed in the same manner.  The final
concentration of the sulfhydryl group reagent in the assay after dilution was 4 µM.
Reactions were started with the addition of substrate. Results are recorded as the percent
of original activity and as the percent inhibition of the post-incubation control.
The effect of particular sulfhydryl - modifying reagents, DTT and DTA, upon
Glo-II preparations that exhibited differing extents of inhibition by ATP (due to the loss
of sensitivity) were also investigated further.  The concentration of stock solutions of the
sulfhydryl group reagents were standardized by spectrophotometric determination of the
chromophore produced by incubation of the reagent with the sulfhydryl group reagent
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DTNB ( ε = 13,600 at 412 nm).  The residual amount of reagent present during the
incubation periods was determined in the same manner.  Incubations were conducted in
buffer A at 1°C.  Samples were removed from the incubation mixtures at appropriate time
intervals and diluted 50-fold into buffer A containing 0.2 mM DTNB in order to quench
any further reactions between the enzyme and reagent.  Controls with no reagent present
were treated similarly.  The enzyme activity was then assayed in the absence and
presence of 2 mM ATP and compared to controls.
Removal of DTA from Glo-II after Incubation with DTA
Removal of the residual DTA from the enzyme after incubation was achieved by
adding an excess of DTNB to the solution to quench any further modification reaction.
Four volumes of cold acetone (-20°C) were then added slowly to the solution with gentle
mixing, and the solution was incubated for 6 hr. at -20°C.  The solution was then
centrifuged at 14,000 x g for 1 hour at 5°C.  The supernatant solution, which contained
the DTA-DTNB complex, was discarded.  The pellet was then dissolved in 1 mL of ice
cold buffer and the process was repeated.  The resulting Glo-II sample was then used for
further kinetic studies.
Gel Filtration of Glo-II
Concentrated Glo-II (50 uL of a 20 U / mL solution) was applied to a G-75
Sephadex column (50 cm × 1 cm), that had been equilibrated with 3 volumes of buffer A
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containing 100 mM NaCl.  Fractions (0.25 mL) were eluted from the column at a flow
rate of 0.25 mL / minute and assayed as previously described.
The column was then equilibrated as before with the same buffer medium
containing 1 mM ATP.  Again, concentrated Glo-II (50 uL of a 20 U / mL) was applied
to the column, eluted with the modified buffer solution, and assayed as before.
Fast Performance Liquid Chromatography  (FPLC) of Glo-II Samples
The elution profiles of Glo-II samples were determined on a Superdex 200 HR
10/30 high performance gel filtration column.  The column was first equilibrated with a
buffer medium containing 40 mM TES and 100 mM NaCl buffer at pH 7.2.  Samples
containing 50 ug of purified Glo-II, 100 uL volume, in buffer A, pre-filtered with a 0.45
µm filter were then applied to the column.  Protein was eluted from the column at a flow
rate of 0.5 mL / min.  Fractions (0.25 mL / fraction) were collected and as assayed as
described previously.
Circular Dichroic (CD) Analysis of Glo-II
Purified samples of Glo-II were analyzed by circular dichroic analysis over the
far-ultraviolet CD spectra, range 190 – 260 nm, 0.1 cm path length, constant bandwidth
of 1.50 nm, at 15°C with a Jasco spectropolarimeter.  Spectra were analyzed using 3
seconds of integration time per reading, and were repeated 3 times.  Signals at each
wavelength were then averaged and digitally filtered by an AVIV 60DS version 4.1g
digital-smoothing program.  The process was repeated using appropriate blanks and
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spectra were corrected accordingly.  The concentration of protein in the sample was 8
µM.  The buffer used was 10 mM TRIS, pH 7.4.
Temperature Denaturation of Glo-II
Purified samples of Glo-II were denatured and analyzed by circular dichroic
analysis at 220 nm, 0.1 cm path length, constant bandwidth of 1.50 nm, with a Jasco
spectropolarimeter.  Readings were analyzed using 3 seconds of integration time per
reading, and were repeated 3 times.  The range of temperatures in which data were
collected was from 25°C to 89°C, with temperature steps of 2.0°C, 0.2 min. equilibration
time.   Signals at each temperature were then averaged and digitally filtered by an AVIV
60DS version 4.1g digital-smoothing program.  The process was repeated using
appropriate blanks and spectra were corrected accordingly.  The concentration of protein
in the sample was 8 µM.  The buffer used was 10 mM TRIS, pH 7.4.
Tryptophan Fluorescent Emission Spectra of Glo-II Samples
The tryptophan fluorescent emission spectra of purified samples of Glo-II were
analyzed in an SLM-Amico Bowman II luminescence spectrometer, excitation
wavelength 280 nm, over a range of 310 to 500 nm.  Further analysis of the samples was
conducted by anisotropic analysis of the spectrum over the same range of wavelengths.
The protein concentration of all samples analyzed was 8 µM. Buffer used was 10 mM
TRIS, pH 7.4.
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Sulfhydryl Group Determination of Glo-II
Sulfhydryl determination of purified Glo-II-s and Glo-II-i preparations were done
according to the method of Kosower (236).  Typically, 20 uL of a 50 mM solution of
monobromobimane was added to 200 uL of an 8 µM solution of Glo-II preparations in 10
mM TRIS buffer, pH 7.4.  Glo-II preparations, 8 µM in 10 mM TRIS, 200 uL, were also
treated with 6 M urea before the addition of the bimane solution. The fluorescent
emission spectra of purified samples of Glo-II were analyzed in an SLM-Amico Bowman
II luminescence spectrometer over a range of 400 to 600 nm as previously described
(237).  Appropriate controls, with no enzyme added, were treated similarly for





The purification of Glo-II-s from bovine calf liver was successfully accomplished
by the rapid affinity chromatography method described in the Methods section.  Table
VIII summarizes the data from a typical purification of Glo-II-s.  The 612-fold purified
enzyme exhibited a specific activity of 1549 U / mg of protein.  The above purification
factor is based on the 14,000 × g supernatant fraction obtained from a calf liver
homogenate.
Glo-II-s – Estimation of Molecular Weight and Analysis of Purity.
Molecular weight estimation and analysis of the purity of the purified bovine calf
liver Glo-II-s were obtained by SDS-PAGE (Figure 1). Both Coomassie blue (not shown)
and silver staining (Figure 1) were used to analyze the purity of the samples.  Coomassie
blue staining procedures showed that Glo-II-s appears to be a single polypeptide chain
that has been purified to homogeneity.  Silver staining procedures, at times, revealed
minor impurities in the samples, although the purity of the samples was estimated to be as
high as 95 percent pure. The relative mobility of the protein sample after purification
(lane 2) was compared to that of a set of standard molecular weight proteins (lane 1) and
analysis of this comparison gave an approximate molecular mass of 29,000 daltons.
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Glo-II-s - Stability with respect to temperature.
We had observed in our initial experiments with the purified fractions of
Glo-II-s that the enzyme activity appeared unstable at elevated temperatures.  Therefore,
the stability of Glo-II-s at a variety of temperatures was determined in order to set
temperature parameters to be used in future studies.
Long term storage of concentrated aliquots of Glo-II-s at -80°C was typically
limited to approximately two months of storage before a significant loss of activity
(>10%) was detected.  Upon removal from these storage conditions and dilution, enzyme
activity proved to be relatively stable for at least 1 hr. when incubated at 12°C or below
but rapidly lost activity when stored at higher temperatures (Figure 2).  At 17°C, more
than 30 percent of the initial activity was lost over a 1 hr. period.  At 22°C, over 50
percent of the initial activity was lost in the same time period.
Since the long-term stability of Glo-II-s was limited, a number of precautions
were taken.  Purified samples of concentrated Glo-II-s were divided into small aliquots
and stored at -80°C until use. Typically, aliquots were removed from the -80°C storage
conditions, diluted with ice cold buffer, and assayed under standard conditions to
determine if any significant loss of activity had occurred during storage.  All experiments
were conducted on samples that exhibited only minor losses of activity during storage
(<10%).
Since the short-term stability of Glo-II-s during experiments was also limited,
additional precautions were taken. During experiments, the diluted aliquots of enzyme
was maintained on ice until use and assayed periodically to detect any losses of activity.
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Incubation experiments were also conducted at or below 12°C whenever possible.
Control samples of enzyme were included in all experiments to determine if any changes
in enzyme activity were due to the instability of the enzyme.  Assays, which were
typically done at 25°C, were conducted over 45 sec. periods to minimize any loss of
activity.
Glo-II-s – Stability with respect to pH.
In order to set the experimental parameters to be used in subsequent studies, the
stability of Glo-II-s with respect to pH was determined.  Studies were conducted to
determine the stability of Glo-II-s during short-term incubation of the enzyme over a
wide range of pH values.  Aliquots of Glo-II-s were incubated at pH values from 4 to 10
for 5 min. at 1°C and assayed under standard conditions (see Methods).  Experiments
revealed that Glo-II-s activity is stable under these conditions over a pH range from 5.5 to
8.5 (Figure 3).  A rapid loss of enzyme activity was detected when samples were
incubated at pH conditions outside of this range.  Due to these results, all further
experiments were conducted within a pH range of 5.5 to 8.5.
Glo-II-s – Activity with respect to pH.
Studies were conducted to determine the activity of Glo-II-s over the range of pH
values from 5.5 to 8.5.  The determination of Glo-II activity is dependent upon the
spectrophotometric detection of the GSH-DTNB complex, but the extinction coefficient
of this complex changes dramatically over the pH range used in these studies.
Furthermore, the rate of the formation of the GSH / DTNB chromophore may also
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change over the pH range used in these experiments.  Experimental conditions were
modified such that the effect of aforementioned changes in the characteristics of the
 GSH – DTNB complex due to pH would not effect the results.
 Experimental conditions were set as follows.  First, reaction mixtures at the
specified pH were incubated, without DTNB present, for a predetermined time period
over which the reaction was shown to be linear.  Second, reactions were quenched by the
addition of acid.  Finally, the pH was adjusted to pH 7.3 by the addition of concentrated
buffer / DTNB solutions and incubated at 22°C for five min. before readings were taken
(see Methods section).   Control mixtures with substrate present but no enzyme added
were treated similarly.  No change in the stability and / or spontaneous breakdown of the
substrate was observed under these conditions; also, the rate of chromophore formation
and the extinction coefficient for that chromophore were consistent in all samples.
A graphical representation of the activity versus pH profile of Glo-II-s is shown in
Figure 4.  Glo-II-s activity exhibited a steady increase with an increase in pH over the pH
range tested.
Glo-II-s – Inhibition of activity by nucleotides with respect to pH.
In order to determine the effect of pH on the inhibition of Glo-II-s by nucleotides,
the experiments described above were repeated in the presence of nucleotide and treated
in the same manner. A graphical representation of the Glo-II-s activity in the presence of
nucleotide versus pH profile is also shown in Figure 4.  The raw data from this graph
were utilized to construct Figure 5, which depicts the percent inhibition of Glo-II-s
activity in the presence of nucleotide versus increasing pH.  It is clear from these data
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that significant inhibition of enzyme activity by nucleotides occurs over a narrow pH
range, 6.5-8.0, and that inhibition is greatest at physiological pH (7.4).   It is as yet
unclear whether the results are due to the titration of a residue in the protein or the
phosphate residue of the nucleotide.
Inhibition Studies with Nucleotides.
Since both ATP and GTP were found to inhibit Glo-II-s activity, the specificity of
the inhibition of Glo-II-s by nucleotides was in question.  In order to determine if the
inhibition was restricted to any one class of nucleotide; or if certain nucleotides were
significantly more inhibitory than others, Glo-II-s was assayed in the presence of wide
variety of nucleotides.  Assays were at fixed substrate concentrations (0.25 mM SLG) in
the presence of a fixed concentration of nucleotide (2 mM) and the activities were
compared to that of a control (no nucleotide).
Figure 6 shows a typical representation of the results of these experiments.  Other
nucleotides (CTP, NAD+, NADH, NADP+, NADPH, FMN, pppGpp, ppGpp, ApppA,
ADPR, and PolyA) were tested as well, but since they showed no, or very little,
inhibition of Glo-II-s activity, they are not shown in the figure. Among the nucleotides
tested, we found that inhibition of the Glo-II-s activity is essentially restricted to four
compounds: ATP, ADP, and GTP, GDP.  It is apparent that only purine nucleotides
possessing a phosphoanhydride bond are effective inhibitors, with ATP appearing only
slightly more inhibitory than the other three.
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Incubation Studies with Nucleotides.
Although ATP appeared slightly more inhibitory than the other purine
nucleotides, the enzyme exhibited no clear preference to any of the four inhibitory
nucleoside di- and tri-phosphates.  We also investigated the effect of pre-incubation of
the enzyme with various nucleotides (1.4 mM), followed by dilution of the incubated
samples into the assay mixture giving a non-inhibitory concentration of nucleotide.   The
results provided further insight into the specificity / effects of nucleotide interaction with
Glo-II-s.  Figure 7 summarizes the results.
Of the nucleotides tested in this manner, only ATP had any significant effect on
the enzyme. Even after dilution of the Glo-II-s / ATP samples to non-inhibitory levels of
ATP, a significant decrease in both activity and the inhibition of Glo-II-s activity, when
assayed in the presence of ATP, was observed.  Attempts to recover the activity or the
original levels of nucleotide inhibition after dilution of the enzyme were met with failure.
Although incubation of the enzyme with GTP does cause a moderate decrease in the Glo-
II-s activity (-10%), no effect on the inhibition of Glo-II-s by ATP was observed.  Thus,
ATP was used as the model inhibitor for further experiments.
Glo-II-s - Kinetic parameters using ATP as a model  inhibitor.
Figure 8 depicts the percent inhibition of Glo-II-s activity by ATP at fixed SLG
concentration (0.25 mM) and increasing ATP concentrations (0-10 mM).  The data show
that 100% inhibition of Glo-II-s activity by ATP could not be achieved, even at levels of
inhibitor as high as 10 mM.  Similar results were obtained with GTP. Values for
maximum inhibition typically ranged from 60-70%.  In pure inhibitor systems, infinitely
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high concentrations of inhibitor will result in the velocity of the enzyme eventually
reaching zero, as the EI complex is incapable of producing product (238).  In the case of
a partial inhibitory process, infinitely high concentrations of inhibitor will result in a
modified form of the enzyme (EI) which is still able to bind to the substrate (ESI) and
produce product but at a reduced rate (238).  Therefore, graphical analysis of a percent
inhibition versus I plot, in the case of partial inhibition, will result in a hyperbolic curve
and plateau at the level of maximum inhibition (the point where all enzyme is in the EI
form).   The hyperbolic nature of the curve resulting from these data suggests ATP or
GTP act as a partial inhibitor of Glo-II-s activity.
Figure 9 is a Lineweaver-Burk plot for the inhibition of purified Glo-II-s by ATP.
Inhibition appears purely non-competitive.  The KM for the natural substrate (0.54 mM
SLG) is approximately 2.5 – 3.5 fold higher than previously reported values (0.18 – 0.22
mM SLG).  Similar results were obtained using GTP.
Of interest was the information obtained from the replots of the experimental
data.  Figure 10 shows the effect of ATP on Glo-II-s activity as analyzed by a Dixon
replot.  Figure 11 shows the effect of ATP on Glo-II-s activity as analyzed by a slope
versus inhibitor concentration replot.  Both replots are obviously parabolic.
Taken together, the data suggests parabolic-parabolic partial non-competitive
inhibition of Glo-II-s activity by ATP (or GTP) and supports the presence of an ESI
complex that is still capable of producing product but at a reduced velocity.  Furthermore,
the finding of partial noncompetitive inhibition and parabolic replots is known to result
from the combination of the inhibitor with two enzyme forms (238).  The presence of two
forms of the enzyme was further supported by the non-linearity of the Eadie-Schatchard
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plot of kinetic data using the same enzyme (Figure 12). Therefore, the data suggest the
presence of two forms of the enzyme in samples tested.
Glo-II-s - Investigation of conditions which cause the loss of inhibition by ATP.
As stated earlier, we had observed the loss of Glo-II-s activity over time even
under optimal storage conditions (- 80°C).  We had also observed a concurrent loss of the
inhibition of Glo-II-s activity by ATP under the same conditions.  This observation was
explored in further detail.
Figure 13 summarizes the results of a typical incubation of Glo-II-s samples when
incubated at 12oC over time.  Aliquots of the enzyme solution were removed from the
incubation periodically and assayed in the absence of ATP (uninhibited activity) and in
the presence of ATP (inhibited activity).  The uninhibited activity of the enzyme
undergoes a steady decrease in activity with time (in this particular experiment the time
period was 33 hr.).  At the end of this period, the remaining activity of the enzyme is
unaffected by the presence of ATP.  No further changes in either the uninhibited or
inhibited activity of the enzyme occurred over the next 24 hr. (data not shown).
As stated earlier, previous experiments involving the short-term incubation of
Glo-II-s with ATP showed a decrease in both the uninhibited activity of the enzyme and
the inhibition of enzyme activity by ATP (Figure 7).  Figure 14 shows the typical effect
of incubation of the enzyme in the presence of high levels of ATP (5mM) under “stable”
incubation conditions (concentrated Glo-II-s at 10C for 2 hr.).  After incubation, samples
were diluted to non-inhibitory levels of ATP (6 µM) and assayed for both activity and
inhibition by ATP.  As in the temperature desensitized sample of Glo-II-s, a loss of both
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enzyme activity as well as the inhibition of activity by ATP had occurred.  Attempts to
recover either the activity or the inhibitory properties of ATP after dilution met with
failure in earlier experiments.
Both procedures that cause the loss of sensitivity of Glo-II-s preparations
presented here have proved to be consistent methods for producing Glo-II-i samples.
Furthermore, the samples can be re-purified by the affinity chromatography step of the
purification process presented earlier.
Glo-II-i - Kinetic parameters.
Glo-II-i, obtained by the desensitization of Glo-II-s by incubation at 12oC, was re-
purified using the last two steps of the purification process (acetone precipitation and
affinity chromatography) to remove any denatured protein from the samples. The
resulting samples were then used in the following experiments.
Figure 15 compares the percent inhibition of Glo-II-s activity by ATP to that of
the Glo-II-i samples desensitized by incubation at 12°C.  Both samples were assayed at
fixed SLG concentration (0.25 mM) with increasing ATP concentrations (0-10 mM).
The ability of ATP to inhibit Glo-II-i is still apparent, although the maximum levels of
inhibition (< 20%) at very high levels of ATP (10 mM) are greatly reduced when
compared to those of the Glo-II-s samples assayed under the same conditions.
Figure 16 shows the Lineweaver-Burk plot for the purified Glo-II-i sample after
temperature desensitization and re-purification.  The enzyme exhibits linear kinetics over
the substrate range used and the value for the KM is 0.22 mM for the substrate, SLG.  The
specific activity of the enzyme was 750 U / min. / mg.  These values are in close
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agreement with previously reported values (Table III).  In Figure 17, an Eadie-Scatchard
replot of the data from Figure 16 shows linearity.  Such linearity is found in such replots
when only one kinetically distinguishable form of an enzyme is predominant in the
sample (238).
Glo-II-i, after desensitization by incubation with ATP, was also re-purified using
the last two steps of the purification process to remove any denatured protein and residual
ATP from the sample.  Figure 18 compares the percent inhibition of Glo-II-s activity by
ATP to that of the Glo-II-i samples desensitized by incubation with ATP.  Both samples
were assayed at fixed SLG concentration (0.25 mM) with increasing ATP concentrations
(0-10 mM).  As with the Glo-II-i preparation desensitized by incubation at 12°C,
nucleotide inhibition of the ATP-desensitized Glo-II-i also remains apparent but is very
much greatly reduced.
Figure 19 shows the Lineweaver-Burk plot for the re-purified Glo-II-i sample
desensitized by ATP incubation and then re-purified.   Lineweaver-Burk analysis gave a
linear plot with a KM = 0.22 mM SLG.  The specific activity of the enzyme was 650 U /
min./ mg.  Again, these values are in close agreement with previously reported values
(see Table III).  The values determined for the Glo-II-i samples desensitized by
incubation at 12°C and by incubation with ATP are also in close agreement.  In Figure
20, an Eadie-Scatchard replot of the data from Figure 19 again gives a linear plot,
suggesting that only one kinetically distinguishable form of the enzyme is present after
this process.
The two procedures described above result in what appear as kinetically similar
enzymes.  Both procedures result in a preparation of Glo-II-i that exhibits only one
76
detectable form of the enzyme as determined by the Eadie-Schatchard replots and have
similar KM values for SLG.  Finally, both procedures result in a form of Glo-II that is no
longer significantly inhibited by ATP.
Each of these “desensitization” procedures can be separated into two steps;
incubation and re-purification.  Analysis of the kinetic characteristics of the enzyme after
each individual step was then completed in order to determine at which point in the
procedure that the KM value of the enzyme for the substrate had changed.
With respect to the Glo-II-i sample formed by incubation of Glo-II-s at 12°C, the
enzyme activity gave similar KM values (0.22 mM) either at the end of the incubation
period or after re-purification (data not shown).  As stated earlier, the Glo-II-s enzyme
before the incubation period gave a KM value of 0.54 mM .  Thus, the change in KM value
for the Glo-II-i sample formed by incubation at 12°C occurs during the incubation period.
The Glo-II-s enzyme was also incubated with ATP (5 mM) as previously
described.  At the end of the incubation period, the enzyme was diluted to a non-
inhibitory concentration of ATP (6 µM).  The enzyme activity at the end of the
incubation period resulted in a KM value of 0.53 mM, a value in close agreement with the
KM value of 0.54 mM for the Glo-II-s sample before incubation (data not shown).   Thus,
the change in KM value for the Glo-II-i sample desensitized by incubation with ATP does
not occur during the incubation period.
The Glo-II-s enzyme was also incubated with ATP (5 mM) and re-purified as
previously described.  After the removal of the ATP by re-purification, the resulting Glo-
II-i sample was compared by Lineweaver-Burk analysis at equal protein concentrations to
the original Glo-II-s (before incubation with ATP and re-purification).  Figure 21
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summarizes the results.  The enzyme after re-purification exhibited the characteristic
reduction in KM value (from 0.54 mM to 0.22 mM) that had been described previously.
No significant change in the Vmax was observed.  The initial velocity of the Glo-II-i
enzyme was consistently greater than that of the Glo-II-s enzyme at the substrate
concentrations tested.
Glo-II-s vs.Glo-II-i - Investigation of the Structural and / or Conformational Differences.
Studies were conducted in order to compare possible structural differences
between Glo-II-s and Glo-II-i preparations.  It was postulated that the different kinetic
characteristics between the Glo-II-s and Glo-II-i preparations are due to changes in
enzyme conformation.
Figure 1 compares the molecular weight of the of the Glo-II-s sample (lane 2) to
that of either Glo-II-i samples discussed above (lanes 3 & 4) by SDS-PAGE, detected by
silver staining.  It is apparent that the molecular weight of the enzyme, as well as the
relative mobility of the protein under these conditions, remains unchanged.  Therefore, it
is assumed that the loss of sensitivity to nucleotide inhibition is not due to any change in
molecular weight that could be detected under these conditions.
Figure 22 shows a comparison of the elution profiles of the activity of Glo-II-s
and Glo-II-I, desensitized by incubation at 12°C, samples as determined on a Superdex
200 HR 10/30 high performance gel filtration column.  The graph clearly shows that the
two samples do not significantly differ in their elution patterns.  Gel filtration (using a
G-75 Sephadex gel filtration column) of the Glo-II-i sample desensitized by incubation
with ATP gave similar results (data not shown).  Therefore, it is assumed that the loss of
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sensitivity to nucleotide inhibition was not due to any large change in molecular shape or
size that could be detected by these methods.
Further experiments using the G-75 Sephadex gel filtration elution pattern of Glo-
II samples under varying conditions were also performed.  Equilibration of the filtration
column with 1 mM ATP did not change the elution profile of Glo-II-s activity when
compared to the elution profile of the same protein under the same conditions without
ATP present (Figure 23).  Similar results were obtained for the Glo-II-i samples as well
(data not shown).  Therefore, the addition of ATP does not cause any large change in the
molecular shape of the enzyme samples under these conditions.
Figure 24 shows a comparison of the circular dichroic spectrum of the Glo-II-s
sample as well as the Glo-II-i sample desensitized by incubation at 12°C.  The circular
dichroic spectrum of Glo-II had been previously reported, identifying the protein as a
typical alpha / beta protein (183).  No significant difference between the CD spectrum of
the Glo-II-s and the Glo-II-i samples was apparent.  The spectrum produced for either
Glo-II sample was also in close agreement with that of previously published data.
Therefore, the loss of sensitivity to nucleotide inhibition is not likely due to the loss of, or
large changes in, the native structure of the protein.
Figure 25 shows a comparison of the heat denaturation temperatures of Glo-II-s
and Glo-II-i samples as analyzed by the circular dichroism of the proteins at 220 nm.
Both proteins show similar temperature denaturation curves in which total loss of
secondary structure does not occur until temperatures approaching 80°C. Therefore, the
loss of sensitivity to nucleotide inhibition is not likely to be due to unfolding of the native
structure of the protein.
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Since no gross structural changes in the two proteins could be detected by any of
the tools employed, it was considered possible that the loss of Glo-II sensitivity is due to
micro-environmental changes in the conformation of the protein.  Since the fluorescence
emission spectra of the tryptophan residues of proteins is often used to detect such small
changes in protein conformation, a comparison of the emission spectra of equal molar
amounts of the Glo-II-s sample and the Glo-II-i sample desensitized by incubation at
12°C was made.  Figure 26 shows the results.
Although the amino acid sequence of calf liver Glo-II has not been determined,
the sequence of human liver Glo-II has been reported.  The amino acid sequence of the
enzyme from human liver shows that only two tryptophan residues are present in the
protein (202).  As stated earlier, available sequence data show strong sequence
homologies from species to species and that the enzyme likely evolved from a common
ancestor (203).  Therefore, the presence of two tryptophan residues can be assumed to
exist in the sequence of calf liver Glo-II.
Figure 26 compares the tryptophan fluorescent emission spectra of the two
Glo-II samples tested.  The differences in the spectra are clear in that the Glo-II-i sample
exhibits a large degree of quenching of the emission signal at the lower wavelengths
analyzed when compared to that of the Glo-II-s sample.  The quenching of the signal is
assumed to be due to the greater exposure of this residue to the outer, aqueous
environment of the protein.  The obvious differences in the microenvironment of the
tryptophan residues of the two forms of the enzyme suggests that the protein
conformation has undergone a small change during the transition from the nucleotide
sensitive to the nucleotide insensitive form.
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Excitation of fluorescent residues by plane polarized light (anisotropy) furnishes a
method of further resolution of the heterogeneous fluorescence in proteins that possess
multiple fluorescent residues (239).  If an excited residue is able to move or rotate
appreciably before the fluorescent light is emitted, the fluorescence will be depolarized to
some extent and therefore the signal will decay at a faster rate than a residue that is not
able to move as freely.  Therefore, a conformational change in a protein is often
detectable by changes in the ability of the residues to move or rotate, as determined by
anisotropy.
The assumption that a conformational change occurs in the transition of Glo-II-s
to Glo-II-i, suggested by the comparison of the fluorescent emission spectra of the two
forms of the protein, was further supported by comparison of the anisotropic derived
fluorescent spectra of the two proteins.  Figure 27 compares the fluorescent emission
spectra of the two protein forms under these conditions.  As in the previous experiment,
the differences in the two spectra support that a conformational change in the protein has
occurred in the transition of Glo-II-s to Glo-II-i.
Glo-II-s –Chemical Modification Studies
A series of chemical modification studies were conducted on samples of Glo-II-s
in order to investigate the effect of such modifications on both the activity and inhibition
of Glo-II by nucleotides.  Results from this study were compared to results from chemical
modification studies on Glo-II preparations previously reported in literature.
Previous chemical modification of amino acid residues on purified Glo-II
indicated both a critical histidine and an arginine in the active site (182, 184). Chemical
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modification of the histidine residues of Glo-II-s by diethylpyrocarbonate (Figure 28),
and of arginine residues by phenylglyoxal (Figure 29)decreased activity similarly to that
previously reported, but had no effect on the inhibition of Glo-II by ATP.  Earlier studies
involving chemical modification of serine residues by PMSF had no significant effect on
the activity of the enzyme (182, 184).  Chemical modification of serine residues by
PMSF had no effect on the activity or nucleotide sensitivity of Glo-II-s (data not shown).
The data suggest that the inhibition of Glo-II-s activity by ATP does not involve the
arginine, serine, or histidine residues of Glo-II.
Studies on the effect of the addition of divalent ions or chelation agents were also
conducted due to reports of the binding of a zinc ion to Glo-II and its proposed
requirement for catalytic activity (191).  The addition of EDTA, EGTA, or 8-
hydroxyquinoline to incubations of pure Glo-II-s exhibited no effect on either enzyme
activity or its inhibition by ATP (data not shown).  Furthermore, the addition of divalent
metal ions (Zn2+, Mn2+, or Ca2+) to the enzyme produced no effect on either enzyme
activity or its inhibition by ATP (data not shown).  Of notable interest was the lack of any
requirement for Mg2+ with respect to the inhibition of enzyme activity by ATP (data not
shown).
Glo-II – Effect of Sulfhydryl Group Modification on Activity and Inhibition by ATP
Uotila reported the stabilization of purified Glo-II from human liver by the
addition of high concentrations of reducing agents such as BME and DTT (168).  Other
studies have reported the loss of Glo-II activity upon the addition of sulfhydryl group
reagents, including alkylating agents (iodoacetate), oxidizing agents (HgCl2), and agents
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known to react with disulfides (CdCl2 and Arsenite) (168, 182, 184).  Since no protection
from the loss of activity was observed in the presence of slow substrate, the presence of
free thiol group(s) located away from the active site, but somehow involved in the
hydrolase activity of Glo-II, was proposed (184).
The deduced amino acid sequence of human liver Glo-II reveals a 260 amino acid
protein with six cysteine residues found dispersed between residues 104 to 171 (202).  As
stated earlier, Glo-II is predicted to be organized into two distinct domains (183).  The N-
terminal domain, residues 1-180, is predicted to be a compact, stable domain consisting
exclusively of beta-sheet secondary structure in which the active site is present.
Therefore, all of the cysteine residues are predictably found in the N-terminal domain.
To date, no analysis of the number of free sulfhydryl groups present in Glo-II has been
reported.
As stated earlier, purified Glo-II-s activity proved to be relatively unstable.
Attempts to stabilize the activity by the addition of DTT proved futile (data not shown).
Notably, these results were contrary to those previously reported by Uotila (168).
Experiments were also conducted using mono-bromobimane, a fluorescent reagent highly
specific for free sulfhydryl groups, to determine if any free cysteine sulfhydryl groups
were present in the protein.  Neither Glo-II-s nor Glo-II-I, desensitized either by
incubation at 12°C or by incubation with ATP, exhibited the presence of free cysteine
groups under both native or denatured by the addition of 6 M urea states.  Therefore, we
assumed that the cysteine residues of bovine calf liver Glo-II are possibly in the oxidized
form, likely as three disulfide groups.
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These findings were further supported by studies of the effect of sulfhydryl
reagents on Glo-II-s activity or inhibition of its activity by ATP.  Results are summarized
in Figure 30.  Neither NEM, GSH, GSSG, or DTNB exhibited any effect on Glo-II-s
activity or its inhibition by ATP.  Diamide, a reagent known to cause the formation of
disulfide bonds with accessible free sulfhydryl residues (240), did exhibit a minor effect
on enzyme activity, but no significant effect on the sensitivity of the enzyme to ATP was
observed.  Longer incubation periods of the enzyme in the presence of these reagents
produced no further effect (data not shown).
 Of great interest was the effect of chemical modification of Glo-II-s with
Meos-2,5-dimercapto-N,N,N’,N’-tetramethyl-adipamide (DTA), a reagent known to
efficiently cleave disulfide bonds at physiological pH.  Incubation of purified Glo-II-s in
the presence of a low concentration of DTA (1 mM) produced a moderate decrease in the
activity of Glo-II-s.  Surprisingly, the reagent also produced a moderate increase in the
inhibition of the sample by ATP (from 42-50 %).  Although the increase in inhibition was
slight, it warranted further study.
Figure 31 depicts a typical time course study of the effect of DTA on the
activity of the Glo-II-i enzyme desensitized by incubation at 12°C.  Incubation was done
in the presence of a high concentration of the reagent (4 mM) at 10C over 10 hr..  Results
show an initial period of stability (5 hr. in this case), followed by a period of significant
loss of enzyme activity.  Figure 32 shows the effect of DTA on the same enzyme solution
with respect to inhibition by ATP.  Results show that during the initial period of stability,
inhibition of the enzyme activity by ATP (2mM) increased steadily.  No significant
change in inhibition was observed after the enzyme had begun to lose activity.  Similar
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results were found with the Glo-II-i desensitized by the addition of ATP (data not
shown).
Experiments were also performed on the Glo-II-s form of the enzyme under the
same conditions (4 mM DTA, 10C).  In contrast to the initial period of stability observed
during the incubation of the Glo-II-i samples with DTA, the Glo-II-s form of the enzyme
exhibited immediate and significant losses of activity in the presence of the reagent
(Figure 33).  In contrast to the immediate increases in the level of inhibition of enzyme
activity by ATP observed during the incubation of the Glo-II-i samples with DTA, the
Glo-II-s form exhibited only moderate increases in the ability of the enzyme to be
inhibited by ATP (Figure 34).
The differences in the effects of DTA on the two forms of the enzymes led us to
investigate the kinetic parameters of the enzyme forms after modification.  The DTA was
removed from these samples and used in kinetic studies.  Figure 35 shows the
Lineweaver-Burk plot for the inhibition of DTA-modified Glo-II-s sample by ATP.  It
was determined that ATP still binds non-competitively to DTA-modified Glo-II.
Furthermore, the KM for the natural substrate (0.6 mM SLG) is significantly higher than
previously reported values (0.18 – 0.22 mM SLG), and slightly higher than the KM for the
Glo-II-s fraction reported earlier herein (0.54 mM SLG).  Figure 36 shows the effect of
ATP on the DTA-modified Glo-II activity as analyzed by a Dixon replot.  Figure 37
shows the effect of ATP on DTA modified Glo-II as analyzed by a slope versus inhibitor
concentration replot.  Replots show that the parabolic curve of the original mixture of
enzyme forms in the Glo-II-s preparation is no longer evident.  Figure 38 shows a linear
Eadie-Schatchard plot of kinetic data obtained from the same enzyme sample.  Attempts
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to reach the level of 100% inhibition met with failure, with the maximum level of
inhibition typically reaching no more than 70% (data not shown).  Similar results were





With but one exception (25), there is no mention of purine nucleotide inhibition of
Glo-II, in crude or purified preparations, in the literature.  Little, if any, purine nucleotide
inhibition of Glo-II is found when the enzyme is purified by traditional methods, which
require multiple chromatography steps and may take days to complete.  The process for
the purification of Glo-II developed in this laboratory is a very rapid method (12 hours or
less) that requires only a single chromatography step.  The resultant enzyme, Glo-II-s, is
significantly inhibited by physiological concentrations of ATP or GTP.
Attempts to define any single step or reagent in previously used purification
methods that was responsible for the loss of inhibition of Glo-II-s activity by ATP met
with failure (Norton, S., Giovanni, B., and Elia, C., unpublished results).  In earlier
studies, attempts to purify large quantities of the enzyme in this “sensitive “ form using
the same basic protocol presented here, but requiring a longer period of time, generally
resulted in a significantly decreased sensitivity to purine nucleotide inhibition (Norton S.
and Elia, C. unpublished results).  It was not until we adopted a more rapid method of
purifying small quantities of the enzyme that the purification process resulted in an
enzyme that was “sensitive” to purine nucleotide inhibition.  Such observations suggest
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that the length of time and / or the complexity of the method used to purify the enzyme
may affect an important quality of Glo-II, structure or conformation, which confers
sensitivity to certain purine nucleotides.
We have found that purified Glo-II-s preparations are relatively unstable.  Even at
- 80°C, the enzyme activity and / or sensitivity undergoes significant losses over time.  At
higher temperatures, the loss of these characteristics are observed to be quite rapid
(Figure 13).  In contrast, the Glo-II activity and / or sensitivity of both the crude
homogenates and the acetone fractions have proved to be relatively heat-stable (data not
shown).  Thus, it is likely that the instability of the enzyme begins at, and is a
consequence of, the removal of the protein from stabilizing components of the cytosolic
milieu during the purification steps.  A rapid and simple method is thus necessary to
obtain a purified enzyme that exhibits the same characteristics in the purified state as it
does in the crude fractions.
The purification of Glo-II-s by the method described here results in a relatively
pure fraction, as analyzed by SDS-PAGE (Figure 1), of highly concentrated Glo-II-s (>
3500 U / ml).  The overall yield of the initial enzyme activity was consistently around
40%.  The specific activity of the enzyme (> 1500 U / mg) was consistently higher than
values previously reported (600-900 U / mg).  Finally, the rapid and easy method
produces milligram quantities of the purified enzyme in relatively short time periods.
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Glo-II-s – Experimental Parameters; pH and Temperature
As stated earlier, the stability of both the activity and the sensitivity of Glo-II-s
with respect to temperature is limited.  Precautions were taken throughout our
experiments to insure our results did not reflect the loss of activity or inhibition qualities
of the enzyme.  These precautions are described previously  and will not be further
elaborated upon here.
The effect of pH on the activity of Glo-II has been previously reported (168, 182).
Glo-II, purified from the liver of either rat or human, was reported to exhibit a pH
optimum of activity from 6.8 to 7.5 and to decrease rapidly outside this range (168, 182).
Glo-II-s, purified in the manner presented here, proved to be relatively stable over a
broad pH range, pH = 5.5-8.5 (Figure 3), and in contrast to previously reported results,
exhibits a steady increase in activity with increasing pH over this range (Figure 4).  The
differences in the results may be, in part, due to the methodology used.  Previous reports
did not apparently allow for the possible assay problems related to either the changes in
the extinction coefficient or changes in the rate of formation of the GSH – DTNB
complex over the pH range tested.  Methods used here were designed to account for such
potential problems.  Significant inhibition of Glo-II-s activity by nucleotides is limited to
a very narrow pH range, pH = 6.8-7.6, and is at its greatest at physiological pH
(Figure 5).  These occurrences are likely due to either the titration of a residue within the
protein itself, or the titration of a residue in the substrate or inhibitor.
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Glo-II-s – Inhibition Studies
Studies to determine the specificity of the inhibition of Glo-II-s by nucleotides
showed that the inhibition of Glo-II-s activity is restricted to four of those compounds
tested: ATP, GTP, ADP, and GDP (Figure 6).  Pre-incubation experiments with the
enzyme and each of of these four nucleotides gave further insight into the inhibitory
differences of these nucleotides (Figure 7).  Only ATP was found to cause any significant
change in the enzyme activity or the inhibition of the enzyme activity by nucleotides,
following dilution.  Since other nucleotides could not produce this effect when studied
under the same conditions, ATP appeared as the most interesting inhibitor / effector of
Glo-II-s and was therefore used in subsequent experiments to determine the nature and
significance of its effects.
Glo-II-s – Kinetics Studies
Kinetics studies on the purified Glo-II-s enzyme showed linear plots over the
substrate range tested when analyzed by the double reciprocal plot method of
Lineweaver-Burk; the Km value for SLG was determined to be 0.54 mM (Figure 9).
This value is substantially higher than that reported for the human liver (0.146 mM)
(168).  Although the magnitude of the differences in Km values could possibly be
attributed to differences in procedure / methodology, the presence of a form of Glo-II not
yet studied, with a higher Km value for SLG may be an alternative explanation.
The data suggest that the inhibition of Glo-II-s activity by ATP is partial non-
competitive in nature (Figures 8, 9).  Thus, the inhibitor forms a complex with the
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enzyme (EI) that is still capable of binding to the substrate (ESI) but the ESI complex
produces product at a reduced rate (238).  The enzyme purified by the method presented
here not only exhibits a higher Km value for the substrate; the maximum velocity of the
enzyme, in the presence of inhibitory concentrations of ATP, is also greatly reduced.
Replots of the kinetic data, employing both slope versus inhibitor concentration or
Dixon replots, show parabolic characteristics (Figures 10, 11).  Parabolic replots occur
with partial non-competitive inhibition of enzyme activity only when the inhibitor is
binding with two different forms of the enzyme, each form with significantly different
affinities for the inhibitor (238).  This suggestion was further supported by the non-
linearity of the Eadie-Schatchard replot of kinetic data from subsequent experiments with
Glo-II-s (Figure 12).  These results suggest that the purification of Glo-II by the method
presented here results in the purification of two forms of the enzyme, one of that exhibits
a significantly higher affinity for ATP than does the other.
The possibility of two forms of the enzyme in the purified fraction was not
unexpected.  We had already noted that the enzyme lost sensitivity during more
conventional purification processes.  Our previous studies had suggested that the process
involved in the loss of nucleotide sensitivity by purified Glo-II probably began during the
chromatography stage of purification.  It was not surprising that our process resulted in
some percentage of the enzyme reverting to this insensitive form, regardless of how rapid
the purification process was.  Due to these results, a major focus of our further research
was to find methods of producing fractions that contained predominantly only one form
of the enzyme.
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Glo-II-s – Possibility of a Variant Regulatory Nucleotide Binding Site
The binding of mononucleotides to various proteins, in which a phosphate or
adenylate transfer occurs, requires the presence three highly conserved motifs (Kinase-1,
Kinase-2, and Kinase3) that form a “catalytic” nucleotide-binding site (242).   Kinase-1
is identified by the highly conserved “Walker” sequence, GXXXXGXK.  Kinase-2
contains an invariant aspartate residue that is responsible for the coordination of the
required ATP-Mg2+ complex during phosphate transfer in these catalytic reactions.  Both
of these motifs outline the peptide segments that bind the phosphate residues of the bound
nucleotide. Kinase-3 is thought to be the peptide segment that binds to the purine or
ribose portion of the nucleotide, thus determining the specificity of the protein-nucleotide
interaction.  Generally, these proteins are often highly specific for one nucleotide, and
rarely are known to bind other nucleotides to the same site.
A second type of “regulatory” nucleotide-binding site, one that is devoid
of catalytic activity, has been defined in a number of other nucleotide-binding proteins
(242). These regulatory sites are apart from the catalytic site of the enzyme and often
reversibly bind more than one nucleotide to the same site. Examples include aspartate
carbamolyltransferase (binds ATP as a positive effector and CTP as a negative regulator),
and phosphofructokinase (binds ADP as a positive effector, phosphoenol pyruvate as a
negative regulator).  Other examples include phosphoglycerate kinase, as well as four
pyrimidine nucleotide kinases (uridine, thymidine, deoxythymidine, and cytidine
kinases).  Uridine kinase binds both UTP and CTP to its regulatory site.  Similar results
were found for thymidine kinase.  Each of these enzymes contain both a catalytic
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nucleotide-binding site (which requires the ATP- Mg2+ complex) and a separate and
distinct regulatory site.  Thus, whether or not the ATP- Mg2+ complex is required in the
binding of a nucleotide to the regulatory site of these proteins is difficult to determine.
The consensus sequences of these regulatory sites are separated into two domains,
Reg-1 and Reg-2 (242).  Reg-1 is responsible for the binding of the base moiety of the
nucleotide and thus determines the specificity of the protein-nucleotide binding.  The
consensus sequences of this domain are considered speculative as they often exhibit a
lower specificity for nucleotides than do catalytic nucleotide binding sites.  Reg-2 is the
domain responsible for outlining the peptide segments that bind the phosphate residues of
the bound nucleotide.  The consensus sequences in this domain exhibit both variant levels
of substitution and spatial arrangement as well.  A highly conserved tyrosine residue,
whose function is as yet undefined, is found within this domain.  The secondary structure
of these motifs is yet to be determined.
The amino acid sequence of Glo-II from human liver or Arabidopsis thaliana
does not possess the conserved sequences that are required for the formation of the
catalytic nucleotide-binding site.  Furthermore, our studies do not find that the binding of
ATP to Glo-II-s requires the presence of Mg2+; nor is the activity / sensitivity of the
enzyme affected by any divalent cation tested.  Although catalytic nucleotide-binding
sites generally bind only one nucleotide, we have shown that four different nucleotides
bind to Glo-II.  Thus, it is highly unlikely that Glo-II-s is a protein in which a “catalytic”
nucleotide-binding site is present.
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Although no Reg-1 domain can be identified in Glo-II, it is known that the
consensus sequence for this domain is highly variable and may not be distinguishable.
The sequence of GLO-II from human liver or Arabidopsis thaliana does contain a
possible variance of the Reg-2 domain.  Three possible Reg-2 nucleotide-binding
domains, each of which overlaps the other and utilizes the same conserved tyrosine
residue (tyrosine-76), are found between residues 35 – 82 in the amino acid sequences of
Glo-II from either source.  Each of these sites contains a possible insertion of a valine
residue within the consensus sequence.  The presence of a regulatory nucleotide-binding
site in GLO-II is therefore possible, given the known variances in the consensus
sequences of the two domains.
Other similarities in the binding of nucleotides to both Glo-II-s and other
enzymes, which are known to possess “regulatory” nucleotide binding sites, are apparent
as well.  We have shown that Glo-II-s binds more than one nucleotide, as do these
regulatory sites.  The binding of nucleotides to Glo-II-s occurs at a site apart from the
catalytic site of the enzyme, similar to that of nucleotide binding to regulatory sites.
Furthermore, the binding of nucleotides to Glo-II-s is apparently not of the “catalytic”
type of binding described above, thus the ATP-Mg2+ complex may not be required for
binding.  These regulatory sites are generally found in proteins that form multimers; the
existence of multimer forms of Glo-II has been previously reported (181).
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Glo-II-i – Preparation from Glo-II-s
Two methods were developed in our laboratory to produce samples of Glo-II-i for
comparative studies.  The incubation of the Glo-II-s preparations at 12°C consistently
resulted in a gradual decrease of the enzyme activity (Figure 13).  Coupled with the
decrease in activity, the inhibition characteristics of the enzyme preparations also
decreased in a parallel manner.  Although the time period of incubation for the
completion of the process varied from sample to sample, this “slow” process of de-
sensitization consistently resulted in an enzyme preparation that exhibited greatly reduced
inhibition when assayed in the presence of ATP.
The incubation of the Glo-II-s enzyme in the presence of high concentrations of
ATP was shown to cause a similar, but much more rapid decrease in enzyme activity
(Figure 14).  As with the de-sensitization of Glo-II-s by incubation at 12°C, the inhibition
characteristics of the Glo-II-s enzyme decreased in a similar, rapid, manner.  Again, the
time period of preparation for the completion of this “rapid” process of de-sensitization
varied from sample to sample, but the process consistently resulted in an enzyme solution
that exhibited greatly reduced inhibition when assayed in the presence of ATP.
Both de-sensitization processes caused some loss of enzyme activity and the near
complete loss of the inhibition of the enzyme by ATP.  These insensitive enzyme
preparations thus obtained were then re-purified to remove any degraded protein, and
ATP, from the solutions, and then used for further study.  These re-purified preparations
were designated as Glo-II-i.
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Glo-II-i – Kinetic Properties
Both procedures for the de-sensitization of Glo-II-i result in enzyme preparations
that exhibit linear plots over the substrate range tested, as analyzed by the double
reciprocal plot method of Lineweaver-Burk (Figures 16, 19).  Further, these enzyme
preparations exhibit equal Km values for SLG (0.22 mM), a value that is approximately
2.5-fold lower than the value determined for the enzyme activity before de-sensitization
(i.e., Glo-II-s, Km = 0.54 mM).
The inhibition of Glo-II-i by ATP is greatly diminished when compared to that of
Glo-II-s (Figures 15, 18).  At physiological concentrations of ATP (2 mM), inhibition
was approximately 15% for the Glo-II-i enzyme.  Maximum inhibition of Glo-II-i was
approximately 20% at 10 mM ATP.  In contrast, the Glo-II-s enzyme was inhibited to a
significantly greater extent when assayed in the same manner (> 50% inhibition at 2 mM
ATP, approximately 65% inhibition at 10 mM ATP).
Since the inhibition of the insensitive enzyme was low, the use of replots of
inhibition data to determine the number of enzyme forms was not practical.  Therefore,
the presence of more than one form of enzyme in the desensitized samples was
determined by Eadie – Scatchard replots of the kinetic data in the absence of inhibitor.
This method is capable of detecting the presence of more that one form of an enzyme in a
solution by the non-linearity of the plots, if the two forms exhibit different Km values for
the substrate used.  The linear replots suggest that only one kinetically distinguishable
form is predominant after the process of de-sensitization of Glo-II-s (Figures 17, 19).
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A significant decrease in the Km value of the enzyme for the substrate occurs
along with the loss of sensitivity to nucleotide inhibition when Glo-II-s preparations are
subjected to de-sensitization procedures.  It is interesting to note that the change in the
Km value occurs at different stages in the two de-sensitization processes .  The decrease
in the Km value occurs during the incubation period of the 12°C-de-sensitization process.
For de-sensitization by ATP, the change in the Km value does not occur until after the re-
purification step.  Thus, it is likely that the rate of de-sensitization of purified Glo-II-s
samples observed during incubation at 12°C is greatly accelerated by the presence of
ATP during re-purification.
Although the Km value of the enzyme for SLG decreases during de-sensitization,
the Vmax of the Glo-II enzyme does not change significantly (Figure 21). Utilizing the
different experimental Km values for the two enzyme preparations, the similar Vmax
values, and the constant substrate concentration used for the assay (0.25 mM SLG), the
calculated initial velocity of the Glo-II-i preparation is 1.63-fold greater than the initial
velocity of the Glo-II-s preparation.  Thus, the calculated initial velocities for the two
enzyme forms suggest that, if no enzyme activity is denatured during the incubation, the
transition of Glo-II-s to Glo-II-i should be coupled with an apparent increase in the
activity of the enzyme.  Therefore, the loss of Glo-II activity observed during the de-
sensitization procedures is likely a “real” loss due to the denaturation of some portion of
the enzyme present in the original Glo-II-s mixture of enzyme forms.  Furthermore, the
enzyme form that is denatured during the process is predictably that of the Glo-II-s form
of the enzyme; this assumption is based on the observed loss of the inhibitory
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characteristics of the Glo-II-s preparation during the process.  This assumption is further
supported by the linearity of the Eadie-Scatchard replots of the kinetic data collected
from the Glo-II-i enzyme that suggest the presence of only one form of the enzyme in the
solution after de-sensitization.
If the maximum velocity of the Glo-II-s enzyme does not change when
transformed to the Glo-II-i form, then, by definition, the value for kcat has not changed.
Thus, the higher Km value of the original Glo-II-s preparation for SLG is apparently due
to a change in the dissociation constant (Ks).  This could result from a decrease in the rate
of formation of the encounter complex (ES) between the enzyme and the substrate, an
increase in the rate of dissociation of the ES complex to free enzyme and substrate, or a
combination of both.
Glo-II-s versus Glo-II-i – Structural and / or Conformational Differences
A series of studies was conducted to determine if the different kinetic and
inhibition characteristics of Glo-II-s and Glo-II-i were due to structural or conformational
changes in the enzyme.  No detectable differences in the relative molecular weights, as
determined by SDS-PAGE (Figure 1), or of molecular dimensions of the enzyme, as
determined by gel filtration (Figure 22), were observed.  Neither did the presence of ATP
cause any detectable differences in the gel-filtration profiles of any of the enzyme forms
tested (Figure 23).  Circular dichroic analysis of the two forms of the enzyme revealed no
significant differences in the spectra, suggesting that no major changes in secondary
structure occur when Glo-II-s is converted to Glo-II-i (Figure 24).  Both forms of the
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enzyme (Glo-II-s or Glo-II-i) exhibit nearly identical temperature denaturation curves as
analyzed by the circular dichroism of the two proteins at 220 nm over a temperature
range of 25°C to 90°C (Figure 25).  The high temperature necessary for the complete loss
of the secondary structure of the protein (> 80°C) suggest that Glo-II is a compact,
relatively stable protein structure.  The similarities in the temperature denaturation curves
also suggest that any structural differences between Glo-II-s and Glo-II-i are not likely
due to significant differences in the folding characteristics of the protein.
Since no apparent differences in the structures of the two forms of the enzyme
were detectable by the methods used above, we assumed that any structural differences
must be due to small micro-environmental changes in protein conformation.  This
assumption was supported by the notable differences in the fluorescent emission spectra
of the tryptophan residues of Glo-II-i when compared to that of Glo-II-s (Figure 26).
This assumption was even further supported by the differences in the anisotropic
fluorescent emission spectra of the tryptophan residues of the two protein preparations
(Figure 27).  Therefore, our data suggest that structural differences between Glo-II-s to
Glo-II-i, the loss of the inhibitory characteristics of the enzyme, and the change in the
value of the Km of the enzyme are apparently due to small micro-environmental changes
in protein conformation.
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Glo-II-s; Chemical Modification Studies
Chemical modifications of Glo-II-s were conducted to determine if the
modification of those residues tested effected the inhibition characteristics of the enzyme.
Modification of the histidine or arginine residues of Glo-II-s caused a loss of activity,
similar to that previously reported, but no effect on the inhibition of the enzyme activity
by ATP was observed (Figures 28, 29).  Modification of serine residues had no effect on
enzyme activity, as found in previous reports; no effect on the inhibition of the enzyme
activity by ATP was observed.  Studies on the effect of metal ions (including Mg2+) or
chelation agents had no effect on either the activity or sensitivity of Glo-II-s as well.
Taken together, these data suggest that Glo-II-s responds in a manner similar to that of
previously reported for Glo-II with respect to the chemical modification of certain amino
acid residues of the protein.  Furthermore, the modification of these residues (or the
addition of ions or chelation agents) does not affect the inhibition characteristics of
Glo-II-s.
Re-sensitization of Glo-II-i
The chemical modification of Glo-II-s with a variety of sulfhydryl group reagents
had no effect on either the activity or the sensitivity of the enzyme (Figure 30).
Furthermore, no free sulfhydryl groups in the protein could be detected.  Finally, no
protection from the loss of activity and / or sensitivity was furnished by the addition of
reducing agents such as DTT.  These results, taken together, suggested that the sulfhydryl
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groups of the protein are not involved in the activity and / or sensitivity of the enzyme.
Furthermore, these data suggested that the cysteine sulfhydryl groups of Glo-II-s exist in
the form of disulfide bonds.
DTA is a reagent that has been well documented for its ability to efficiently
cleave disulfide bonds, reducing them into free sulfhydryl groups (241).  The efficiency
of the reagent in this reaction is due to its low pKa (7.8) for the formation of the active
species, the thiolate anion (241).  Other reagents capable of cleaving such bonds
(e.g., DTT) are far less efficient in this reaction due to the characteristically high pKa
values (> 9) for the formation of the active thiolate anion (241).  Furthermore, DTA is
considered far more specific than other reagents used to cleave disulfide bonds (mercury,
cadmium, or arsenic) (241).  Therefore, DTA was employed as a reagent to study the
effect of the reduction of disulfide bonds on the activity and sensitivity of Glo-II-s or
Glo-II-i.
Modification of Glo-II-i by DTA results in two stages of modification; an initial
stage involving re-sensitization followed by a stage involving loss of enzyme activity
(Figures 31, 32).  The re-sensitization stage is thus characterized by the significant
increase in the inhibition of the enzyme by ATP.  No apparent change in the activity of
the enzyme, when assayed at high substrate levels is detectable during this stage.  Once
the re-sensitization of the enzyme appears complete, the second stage is characterized by
the gradual loss of enzyme activity.  No further change in the inhibition characteristics of
the enzyme is observed during this stage.  Long incubation periods result in the complete
loss of enzyme activity.
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Treatment of Glo-II-s with DTA results in a one-stage process that is very similar
to the gradual decreased enzyme activity observed during the incubation of Glo-II-i with
DTA (Figures 3, 34).  Only very small increases in the inhibition characteristics of Glo-
II-s were, at times, observed, while longer incubation periods invariably cause the
complete loss of enzyme activity.
Our findings show that the treatment of Glo-II-i with DTA results in an enzyme
form that is sensitive to inhibition by ATP.  If one assumes that one (or more) disulfide
bond(s) has (or have) been reduced in this process, then the inhibition of Glo-II activity
by ATP requires the presence of at least two free sulfhydryl groups.  If the proposed free
sulfhydryl groups in Glo-II-s were, by some process, susceptible to oxidation, upon
formation of the resulting disulfide bond(s) Glo-II-s would thus be converted back to
Glo-II-i.  The data also suggest if all the disulfide bonds in the protein are reduced (long
incubation periods), complete loss of activity results.
The results from the studies on the incubation of Glo-II with DTA are contrary to
those involving other sulfhydryl group reagents.  It may be that the free –SH groups in
Glo-II-i are inaccessible to the reagents used in these experiments.  The –SH reagents
used may not be sufficiently reactive to effect modification.  Although the nature of the
cysteine residues in Glo-II is still unclear, it is obvious that modification of the enzyme
by this reagent causes the re-sensitization of the enzyme.
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Glo-II-s (Obtained by DTA treatment of Glo-II-i) – Kinetic Characteristics
The DTA-treated enzyme exhibits kinetic characteristics similar to that of Glo-II-s.
The Km for SLG was found to be 0.6 mM and is comparable to the Km for the originally
purified Glo-II-s preparation, 0.54 mM (Figure 35).  The major difference in the kinetic
characteristics of the two enzyme preparations came from analysis of the replots of the
kinetic data (Figures 36, 37).  Replots show that the parabolic curve of the original
mixture of enzyme forms in the Glo-II-s preparation is no longer evident.  The data
support hyperbolic, hyperbolic, partial non-competitive inhibition, and suggest that only
one form is now present in the sample (238).  This suggestion was further supported by
the linearity of the Eadie-Schatchard replot of kinetic data from subsequent experiments
with Glo-II-s (Figure 38).  It is assumed under these conditions that an active ESI
complex is formed that is still capable of producing product, but at a reduced rate.  It is
thus apparent that the enzyme form that is predominant in these preparations is now the
nucleotide sensitive form of the enzyme.  Since the re-sensitized enzyme was observed to
be highly unstable when attempting to remove the DTA by re-purification, yields were
extremely poor.  The value for the specific activity of this preparation was not considered
reliable.
Physiological Implications
As stated previously, quantitative kinetic models predict that Glo-II is a near
optimal catalyst for the hydrolysis of SLG (186, 189, 223).  These models predict that
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Glo-II activity, under physiological conditions with substrate concentrations much lower
than the Km value for the substrate, is significantly limited by the diffusion controlled
collision of the enzyme with the substrate, a major criteria for the optimality of an
enzymatic reaction.  This type of enzymatic activity would be indicative of an enzyme
that operates as the exit step of a detoxification system.  From calculations based on
known values for the kinetic parameters and the cellular concentrations of Glo-II, the
steady-state concentrations of SLG in a cell must be held at low nanomolar
concentrations (2 nM) in order for these models to be valid (223).
Another model for the catalysis of SLG by Glo-II is derived from in vivo studies
in which the predicted optimality of the enzymatic reaction is significantly decreased.
These studies indicate that the steady state concentration of SLG found in cells (15 µM –
20 µM) is three orders of magnitude greater than that predicted by the quantitative kinetic
model (218).  Furthermore, the Glo-II activity of tissues has been reported to exhibit up
to 104 increases in activity upon cell lysis (243).  Finally, in vivo studies have shown that
the Glo-II activity of certain differentiating or activated tissues exhibit changes in such a
manner that a putative, but as yet unidentified non-competitive effector of Glo-II activity
exists within these cells (73, 187).
A great deal of research has been directed toward the effect of certain disease
states on the flux of methylglyoxal through the glyoxalase system.  Disruption of
glyoxalase activity, resulting in changes in the efficiency of the removal of toxic
methylglyoxal from tissues, has been observed in both cancerous (211) as well as diabetic
tissue (220).  In part, these observed changes in system flux may be attributed to changes
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in the concentration of the initial substrate for the system, methylglyoxal.  Alternatively,
studies have predicted that the resulting buildup of glyoxalase metabolites in disease
states is, at least in part, due to dramatic changes in the activity of the glyoxalase
enzymes (211, 220).  In particular, a reduction of the catalytic efficiency of the exit step
of the system, that reaction catalyzed by the Glo-II reaction has been reported (211).
We have demonstrated that two forms of Glo-II are purified by the method
developed in our laboratory.  One of these forms, Glo-II-i, appears as a more optimal
catalyst for the metabolism of SLG due to its greater affinity for the substrate.  As a
consequence of the increased substrate affinity, the enzyme would exhibit a somewhat
higher enzymatic velocity (1.8 fold) with respect to the hydrolysis of the substrate when
compared to that of the Glo-II-s form of the enzyme. Furthermore, ATP does not
significantly inhibit the Glo-II-i form of the enzyme.
In contrast to the Glo-II-i form, the Glo-II-s form appears as a much more
inefficient enzyme in its role of SLG catalysis.  It has a significantly reduced affinity for
the substrate, and furthermore, its catalytic activity, in vivo, would be greatly decreased,
since it would be constantly bathed with inhibitory, cytosolic levels of ATP (2 - 4 mM).
The existence of two forms of the Glo-II, in vivo, suggests three interesting case
scenarios.  Each of these cases can be theoretically true.  Each case also lends itself to
predictive explanations for the aforementioned enigmas, described above, that glyoxalase
researchers are faced with today.
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Case 1:only Glo-II-i exists in the cell: This scenario would be in agreement with the
predictions of the quantitative kinetic models of the glyoxalase system which predict that
the Glo-II reaction is acting at near optimal efficiency.  Our studies suggest that the kcat of
the two forms of the enzyme is the same.  Furthermore, the Km value determined for the
Glo-II-i enzyme (0.22 mM) is in very close agreement with the value used in these
models.  Since the kinetic model is based on the values calculated for kcat / KM for the
enzyme, then in vivo, the enzyme is significantly limited by the diffusion controlled
encounter between the substrate and enzyme and acts at nearly optimal efficiency.
This scenario provides no explanation for the significantly higher levels of SLG
actually found in cells, nor does it provide any explanation for the possibility of the
existence of a non-competitive inhibitor found in cells as predicted by the in vivo studies.
Further, it doesn’t provide for any explanation for the changes in Glo-II activities that
have been reported in diabetic or cancerous tissues.  Finally, the Glo-II-s form of the
enzyme would be relegated to being an artifact of the purification method, a suggestion
that seems unlikely due to the inhibition of Glo-II activity by purine nucleotides found in
crude cytosolic fractions from a variety of life forms.
Case 2; only Glo-II-s exists in the cell: This scenario is in close agreement with the in
vivo predictions that state that Glo-II does not always act in an optimally efficient manner
in cells.  It is in full agreement with the prediction of the existence of a non-competitive
inhibitor of Glo-II activity in cells.  The reduced affinity of the enzyme for the substrate
as well as the reduced velocity of an enzyme that is constantly inhibited by a
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physiological non-competitive inhibitor could, therefore, be responsible for the increased
concentrations of SLG found in vivo.
This scenario would relegate the Glo-II-i form of the enzyme to that of an artifact
of the traditional purification methods previously reported in the literature.  This enzyme
form was most probably that utilized by researchers to develop the quantitative kinetic
models, which predict that Glo-II in cells is acting in a near optimal manner.  The
possibility of the presence of a regulatory nucleotide-binding site in Glo-II-s provides a
putative explanation for the changes in Glo-II activity during the aforementioned disease
states.
Case 3 – both forms exist in the cell and are interconvertible: The existence of two forms
of Glo-II in a cell, that are interconvertible, provides still another scenario to explain the
discrepancies found in comparisons between the in vitro and in vivo studies.  The kinetic
models, which describe an optimally efficient Glo-II, can be explained by noting that the
studies leading to these models did not account for, nor did they consider, the existence
of a Glo-II-s form, which has been demonstrated to exist in the present study.
Discrepancies, such as the increased levels of SLG found in vivo, the proposed existence
of a non-competitive inhibitor in subject cells, and the less than optimal efficiency of the
Glo-II reaction found, may be attributed to the existence of the Glo-II-s form of the
enzyme in cells.  Finally, the changes in Glo-II activity reported to occur in diseased or
stressed tissues (e.g. diabetic or cancerous) may be attributed (at least partially) to
changes in the ratio of the two enzyme forms in cells.  At one extreme, if all the enzyme
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exists as Glo-II-i, and the intracellular SLG concentrate is 20 µM, the rate of the
enzymatic reaction can be calculated to be almost 10-fold higher than when all the
enzyme exists as Glo-II-s.
Of course, the predictions above are entirely hypothetical and are based on
considerable speculation.  Other factors not yet discovered or understood, could be
responsible for the discrepancies found in comparisons between in vitro and in vivo
studies of the glyoxalase system.  At this point, the physiological implications of this
work remain unclear.  It is interesting to envision that the ratio of two interconvertable
forms of the enzyme could be dependent upon stress conditions (e.g., oxidative stress).
The possibility of the presence of a regulatory nucleotide-binding site in Glo-II-s is of
even more interest.  Thus, the interconversion between the enzyme forms or the
regulation of Glo-II activity by nucleotides would be determined by factors that allow an
optimal response to the needs of the cell under varying conditions.
The central outcome of this work is that Glo-II can exist in two kinetically
distinguishable forms that can be co-purified.  More importantly, we have provided the
tools to consistently separate or modify this co-purified pair of enzyme forms such that
only one form of the enzyme is predominant in the preparation and can be further studied.
Finally, and of paramount importance, we have drawn attention to the finding that the
inhibition of the Glo-II activity of cytosolic tissue extracts by nucleotides is an inherent
characteristic of one of the two forms of the enzyme.  The physiological implications of






Content of Glo-I in Adult Human Tissues
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Small Intestine 1.3 0.04
Spleen 2.5 0.08
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Molecular and Kinetic Characteristics of Glo-II
Source Mol. Wt. Isoelectric    Specific Act.     Km                # of  
(kDa) Point      (I.U./ mg)     (µM)            forms
________________________________________________________________________
Cytosolic Form
Human Liver 22.9 8.35      822     146      1
Mouse Liver 29.5 8.1     920     270      1
Rat Liver 24 8, 7.4     ----     351     2
Bovine Calf Brain 23 8, 7.4     ----     351     2
Rat Brain 24 8, 7.4     ----     351     2
Rat Erythrocyte 21.9 ------     773     ----     -
Bact. (H. mrakii) 24 4     ----     80     2
Fungal (Cand. alb.)    29 6     ----    142     1
Yeast (S. cerevisiae) 19 ----                      ----                  ----                   -- 
Plant (Zea mays) 26 4.5      65    137    1
Plant (Aloe vera) 27      4.7, 4.8, 5.0    536    150    3
Plant (Spin.oleracea) 26      5.3, 5.8, 6.2    ----        240, 150, 200    3
Mitochondrial Form
(bovine calf liver)    23-24         6.3 - 7.9                134    290    5
(Spinacea oleracea)  26 4.8    ----    170    1
Data from References 168, 169, 171, 175 – 180, 182, 206
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Table V
Substrate Specificity of Human Glo-II from Human Liver
________________________________________________________________________
Substrate      V max (relative)         Km (µM)
_____________________________________________________________________
S-Lactoylglutathione 100 190
S-Glycerylglutathione   62 109
S-Acetoacetylglutathione  56 295
S-Glycolylglutathione   39   70
S-Formylglutathione   38 153
S-Succinylglutathione   29 200
S-Propionylglutathione   14 213
S-Acetylglutathione    9 266
S-Mandeloylglutathione    5   16
_____________________________________________________________________
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Figure 1; SDS-PAGE of Glo-II Preparations
Analysis of the purity of Glo-II preparations was carried out by SDS-PAGE by the
method of Laemmli (231), using a Bio-Rad mini-gel apparatus, with a 3% acrylamide
stacking gel and a 15% acrylamide resolving gel (see Methods section).  Determination
of the molecular mass of the enzyme was done by comparison of the relative mobility of
the protein to those of a set of molecular mass standards purchased from Sigma.
Detection of the protein was done by silver staining (233).  The amount of protein used
was 10 ng.  Lanes are identified as lanes 1-5 from left to right.  Lane 1 contains standard
molecular mass proteins in descending order from top to bottom and include (in order):
Bovine Serum Albumin (66 kDa)
Glutamic Dehydrogenase (55 kDa)
Ovalbumin (45 kDa)
Carbonic Anhydrase (29 kDa)
Trypsinogen (24 kDa)
Trypsin Inhibitor (20 kDa)
α-Lactalbumin.
Lane 2 contains Glo-II-s.
Lane 3 contains Glo-II-i de-sensitized by incubation at 12°C.
Lane 4 contains Glo-II-i de-sensitized by incubation with ATP.
Lane 5 contains Glo-II-s re-sensitized by incubation with DTA.
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Figure 2; Temperature Stability of Purified Glo-II-s
Glo-II-s (2.5 U / ml) was incubated at various temperatures and aliquots were removed,
diluted, and assayed periodically for activity.  Assays were conducted as described in
Methods section.  SLG concentration in the assay was 0.25 mM.  Data are recorded as the


















Figure 3; The Stability of Purified Glo-II-s with Respect to pH
Aliquots of Glo-II-s (2.5 U / ml) were incubated at pH values from 4 to10 for 5 min. at
1°C in a buffer containing a combination of 40 mM citrate, 40 mM TES, and 40 mM
TRIS (see Methods section).  Aliquots were removed, diluted 20-fold into buffer A, and
then assayed for activity.  Data were recorded as the percent activity of the enzyme after
incubation relative to that of a fresh dilution of an aliquot of the enzyme that had been
incubated in buffer A, 1°C.  Assays were conducted as described in the Methods section.















Figure 4 ; Profile of Glo-II-s Activity and Inhibition by ATP with Respect to pH
Glo-II-s was assayed at pH 5.5-8.5 in a buffer containing a combination of 40 mM citrate,
40 mM TES, 40 mM TRIS, 0.4 mM SLG in 1 ml total volume for 1 min. at 25°C.  The
reaction was started by the addition of substrate.  The reaction was then quenched by the
addition of 300 µL of 1N HCL, and then incubated for  5 min..  The pH of the solutions
was brought to 7.3 by the addition of 2.7 ml of a 1 M TES buffer, pH 7.3, containing 0.8
mM DTNB.  For all samples a blank with no enzyme present was treated similarly.  The
absorbance of each sample was then read at 412 nm against the appropriate blank.  All
assays and blanks were then repeated in the same manner with the addition of 2 mM









































Figure 5; Profile of Nucleotide Inhibition of Glo-II-s with Respect to pH
The data from Figure 4 were used to construct the plot.  The percent activity was
calculated from the ratio of the activity of the enzyme in the presence of nucleotide to


















Figure 6; Inhibition of the Purified Glo-II-s Activity by Nucleotides
Purified Glo-II-s was assayed in the presence of a various nucleotides.  The data were
then compared to the uninhibited activity (no nucleotide present) of the enzyme.  Assays
were conducted as described in the Methods section.  Substrate concentration in the
assays was at 0.25 mM SLG.  Nucleotide concentration was 2 mM.  The percent
inhibitions were calculated from the ratio of the inhibited activity to the uninhibited

















Figure 7; Inhibition of Purified Glo-II-s by Nucleotides under Pre-incubation Conditions
Samples of concentrated Glo-II-s (20 U / ml) were incubated for 1 hr. at 12OC in the
presence of nucleotide (1.4 mM), then diluted (1-500) into the assay medium such that
the residual nucleotide concentration from the incubation was 2.8 µM (a non-inhibitory
concentration). A control with no nucleotide added was treated similarly.  Assays were
conducted at 0.25 mM SLG as described in the Methods section.  Data were recorded as
the percent activity of the enzyme relative to that of the enzyme at time zero and shown
in open bars in the histogram.  Assays were also conducted using 0.25 mM SLG in the
presence of 1 mM ATP to determine if any change in the extent of inhibition by ATP had
occurred.  Data were recorded as percent inhibition relative to that of the enzyme assayed
in the absence of ATP and shown in closed bars in the histogram.  All samples were















































Figure 8; Percent Inhibition of Glo-II-s by ATP
Samples of concentrated Glo-II-s were assayed at varying levels of ATP (0 to 10 mM).
All assays were conducted at 0.25 mM SLG as described in the Methods section.  Data
























Figure 9; Non-competitive Inhibition of Purified Glo-II-s Activity by ATP
The assay method is as described in Methods section.  Velocity is in terms of µmol / min.
of GSH produced from SLG.  SLG concentrations were 0.125, 0.167, 0.25, 0.5, and 0.75
mM.  ATP concentrations were 0, 0.4, 0.6, and 0.8 mM.  Lines were generated using a























Figure 10; Inhibition of Glo-II-s by ATP: Dixon Plot
The data from Figure 9 were used to construct the plot.  Lines were generated using a























Figure 11; Inhibition of Glo-II-s by ATP: Slope versus Inhibitor Concentration Plot
The data from Figure 9 were used to construct the plot. Lines were generated using a
















Figure 12; Glo-II-s, Eadie Schatchard Plot
Assays were conducted as described in the Methods section.  Substrate concentrations
used ranged from 0.025 mM to 0.80 mM.  Lines were generated using a computerized














Figure 13; Desensitization of Glo-II-s by Incubation at 120C
Glo-II-s (2.5 U / ml) was incubated at 120C and aliquots were removed, diluted, and
assayed periodically for activity.  Assays were conducted in the absence of ATP
(uninhibited activity) and in the presence of 2 mM ATP (inhibited activity) as described
in the Methods section.  SLG concentration in the assay was 0.25 mM.  Data are plotted

























Figure 14; Desensitization of Glo-II-s by Incubation with ATP
Samples of Glo-II-s (20 U / ml) with or without 5 mM ATP, at designated times, were
withdrawn and diluted into the assay medium such that residual nucleotide concentration
from the incubation was 6 µM , a non-inhibitory concentration.  Assays were conducted
at 0.25 mM SLG to determine any change in the hydrolase activity of the incubated
enzyme.  Assays were also conducted at 0.25 mM SLG in the presence of 2 mM ATP to
determine any change in inhibition properties.  The control underwent no change in
hydrolase activity or % inhibition during the incubation (data not shown).  Percent
activity was determined by the ratio of the activity of the sample incubated with ATP to
that of the control, where the activity of the control was designated at 100 %.  The





















Figure 15; Percent Inhibition Profile of Purified Glo-II Activity by ATP, Glo-II-s vs. Glo-
II-i Desensitized by Incubation at 12°C
Samples of Glo-II-s were assayed at varying levels of ATP (0 to 10 mM).  All assays were
conducted at 0.25 mM SLG. The percent activity was determined by the ratio of the
activity of the enzyme in the presence of ATP to the activity of the enzyme in the absence
of ATP.  Samples of Glo-II-I, desensitized by incubation at 12°C, were then treated in the


























Figure 16; Lineweaver-Burk Plot of Glo-II-i Activity Desensitized by Incubation at 12°C
The assay method is as described in the Methods section.  Velocity is in terms of µmol /
min. of GSH produced from SLG.  SLG concentrations were between 0.125 and 1 mM.
Lines were generated using a computerized linear regression program.  The KM of the

























Figure 17; Eadie – Scatchard Plot of Glo-II-i Activity Desensitized by Incubation at 12°C
The data from Figure 16 were used to construct the plot. The line was generated using a
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Figure 18; Percent Inhibition of Glo-II from Calf Liver by ATP, Glo-II-s vrs. Glo-II-i
Desensitized by Incubation with ATP
Samples of Glo-II-s were assayed at varying levels of ATP (0 to 10 mM).  All assays were
conducted at 0.25 mM SLG. The percent activity was determined by the ratio of the
activity of the enzyme in the presence of ATP to the activity of the enzyme in the absence



















Figure 19; Lineweaver-Burk Plot of Glo-II-i Desensitized by Incubation with ATP
The assay method is as described in the Methods section.  Velocity is in terms of µmol /
min. of GSH produced from SLG.  SLG concentrations were between 0.125 and 1 mM
SLG.  Lines were generated using a computerized linear regression program.  The KM of

















Figure 20; Eadie – Scatchard Plot of Glo-II-i Desensitized by Incubation with ATP
The data from Figure 19 were used to construct the plot.  Lines were generated using a
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Figure 21; Comparison of the Vmax and KM values of Glo-II-s and Glo-II-i
The Glo-II-s enzyme was de-sensitized by incubation with ATP (5 mM) as previously
described.  After re-purification of the sample, the resulting Glo-II-i preparation was
compared to an equal protein concentration of the original Glo-II-s enzyme by the double
reciprocal plot method of Lineweaver-Burk.   The Glo-II-i form of the enzyme exhibited
the characteristic reduction in KM value (from 0.54 mM to 0.22 mM) that had been
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Figure 22; Comparison of FPLC Elution Profiles of Glo-II-s And Glo-II-i Desensitized
by Incubation at 12°C
The elution profiles of Glo-II samples were determined on a Superdex 200 HR 10/30
high performance gel filtration column.  The column was first equilibrated with a buffer
medium containing 40 mM TES, 100 mM NaCl, at pH 7.2.  Samples containing 50 ug of
purified Glo-II, 100 uL volume, in buffer A were then applied to the column.  Protein
was eluted from the column at a flow rate of 0.5 mL / min.  Fractions (0.25 mL / fraction)


























Figure 23; Gel Filtration Profiles of Glo-II-s - Effect of the presence of ATP
Concentrated Glo-II-s (50 µl of a 20 U / ml solution) was applied to a G-75 Sephadex
column (50 cm × 1 cm), equilibrated with buffer A containing 100 mM NaCl.  Fractions
(0.25 ml) were eluted from the column with the same buffer at a flow rate of 0.25 ml /
min. and assayed as previously described.  The column was then washed extensively with
buffer A containing 100 mM NaCl and 1 mM ATP. Concentrated Glo-II-s (50 µl of a 20
U / ml solution) was applied to the column and eluted with the buffer A containing 100






















Figure 24; Comparison of the Circular Dichroism Spectra of Glo-II-s and Glo-II-i
Desensitized by Incubation at 12°C
Purified samples of Glo-II were analyzed by circular dichroic analysis over the far-
ultraviolet CD spectra, range 190 – 260 nm, 0.1 cm path length, constant bandwidth of
1.50 nm, at 15°C with a Jasco spectropolarimeter.  Spectra were analyzed using 3
seconds of integration time per reading, and were repeated 3 times.  Signals at each
wavelength were then averaged and digitally filtered by an AVIV 60DS version 4.1g
digital-smoothing program.  The process was repeated for corresponding blanks and
spectra were corrected accordingly.  The concentration of protein in the sample was 8































Figure 25; Temperature Denaturation of Profiles of Glo-II-sversus Glo-II-i Desensitized
by Incubation at 12°C
Purified samples of Glo-II were denatured and analyzed by circular dichroic analysis at
220 nm, 0.1 cm path length, constant bandwidth of 1.50 nm, with a Jasco
spectropolarimeter.  Readings were analyzed using 3 seconds of integration time per
reading, and were repeated 3 times.  The range of temperatures in which data were
collected was from 25°C to 89°C, with temperature steps of 2.0°C, 0.2 min. equilibration
time.   Signals at each temperature were then averaged and digitally filtered by an AVIV
60DS version 4.1g digital-smoothing program.  The process was repeated for
corresponding blanks and spectra were corrected accordingly.  The concentration of































Figure 26; Comparison of the Tryptophan Fluorescent Emission Spectra of Glo-II-s
versus Glo-II-i Desensitized by Incubation at 12°C
The fluorescent emission spectra of the tryptophan residues of purified samples of Glo-II
were analyzed in an SLM-Amico Bowman II luminescence spectrometer over a range of
310 to 500 nm.  The protein concentration of all samples analyzed was 8 µM.  Buffer


















Figure 27; Comparison of the Fluorescent Anisotrophy Spectra of Glo-II-s and Glo-II-i
Desensitized by Incubation at 12°C
The fluorescent emission spectra of purified samples of Glo-II were determined in an
SLM-Amico Bowman II luminescent spectrometer over a range of 310 to 350 nm.  The
excitation wavelength used was 280 nm.  Analysis of the samples was conducted by
anisotropic analysis of the spectra.  The protein concentration of all samples analyzed












































Figure 28; Effect of Histidine Modification by Diethylpyrocarbonate on Glo-II-s
Chemical modification of histidine residues was done at 1°C using 1-4 IU of Glo-II-s in
30 mM TRIS, pH 6.0.  The modification reaction was started by the addition an aliquot of
a DEPC / EtOH stock solution (1% EtOh, 6 mM DEPC final concentration).  Aliquots
were removed at appropriate time intervals and assays were conducted as previously
described with and without 2 mM ATP. Results were recorded as percent residual activity
or as percent residual inhibition.  A control was treated similarly and used for




















































Figure 29; Effect of Arginine Modification by Phenylglyoxal on Glo-II-s
Chemical modification of arginine residues was done at  1°C using 1-4 IU of Glo-II-s in
100 mM TRIS, pH 7.7.  The modification reaction was started by the addition an aliquot
of phenylglyoxal / DMSO stock solution (5% DMSO, 5 mM phenylglyoxal final
concentration).  Aliquots were removed and assays were conducted as previously
described, without and without 2 mM ATP added.  A control was treated similarly
(addition of DMSO without phenylglyoxal).  No change was observed in the control
solution (data not shown for clarity).  Results were recorded as the residual % activity
and the residual % inhibition as compared to that of a control sample of enzyme (no
modifier added).  These values were plotted against the time of incubation.  Lines were

















Figure 30; Effect of Sulfhydryl Group Modification on Glo-II-s
Concentrated solutions of Glo-II-s (50 U / ml) containing 5 mM concentrations of either
DTNB, NEM, GSH, GSSG, DTA, or diamide were prepared and assayed immediately
for both activity and inhibition by ATP.  A control sample (no reagent added) was treated
similarly.  The samples were then incubated for 200 min. at 1°C.  Samples were then
diluted (1-1250), and assayed in the presence and absence of 2 mM ATP.  Results are
compared to those of the control.   The control underwent no change detectable changes
in activity or inhibition by ATP during the incubation.  At the end of the incubation
period, all samples were diluted similarly and assayed in the same manner.  Results are
recorded as the % activity or % inhibition remaining after the incubation.  The final
concentration of the sulfhydryl group reagent in the assay after dilution was 4 µM.



















Figure 31; The Effect of DTA on the Activity of Glo-II-i
Incubation of Glo-II-i was done in the presence of 4 mM DTA at 10C over 10 hrs. in
buffer A.  At designated times, aliquots were removed from the incubation and assayed as
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Figure 32; The Effect of DTA on the Inhibition of Glo-II-i by ATP
Incubation of Glo-II-i was done in the presence of 4 mM DTA at 10C over 10 hrs. in
buffer A.  At designated times, aliquots were removed from the incubation and assayed as
previously described in the Methods section without and with 2 mm ATP.  Results are



















Figure 33; The Effect of DTA on the Activity of Glo-II-s
Incubation of Glo-II-s was done in the presence of 4 mM DTA at 10C over 10 hrs. in
buffer A.  At designated times, aliquots were removed from the incubation and assayed as
















Figure 34; The Effect of DTA on the Inhibition of Glo-II-s by ATP
Incubation of Glo-II-s was done in the presence of 4 mM DTA at 10C over 10 hrs. in
buffer A.  At designated times, aliquots were removed from the incubation and assayed as
previously described in the Methods section without and with 2 mm ATP.  Results are
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Figure 35; Lineweaver-Burk Plot of Glo-II Activity after incubation with DTA
The assay method is as described in the Methods section.  Velocity is in terms of µmol /
min. of GSH produced from SLG.  SLG concentrations were from 0.1 to 0.6 mM.  ATP
concentrations were 0, 0.1, 0.2, 0.6, and 0.8 mM.  Lines were drawn using a
computerized linear regression program.  The Glo-II sample was the Glo-II-s sample
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Figure 36; Dixon Plot of Glo-II Activity after Incubation with DTA
The data from Figure 35 was used to construct the plot. Lines were generated using a




















Figure 37; Slope versus Inhibitor Concentration Plot of Glo-II Activity after Incubation
with DTA
The data from Figure 35 were used to construct the plot.  Lines were generated using a


















Figure 38; Eadie – Schatchard Plot of Glo-II Activity after Incubation with DTA
Assays were conducted as described in the Methods section.  Substrate concentrations
used ranged from 0.025 mM to 0.80 mM.  Lines were generated using a computerized
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